Page last updated: 2024-12-06

cromolyn sodium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cromolyn sodium is a mast cell stabilizer that inhibits the release of histamine and other inflammatory mediators. It is used to prevent asthma attacks and allergic reactions. Cromolyn sodium is synthesized by a multi-step process involving the reaction of a substituted benzopyran derivative with a reactive electrophile. Its mechanism of action involves binding to and stabilizing mast cells, preventing the degranulation that releases histamine and other inflammatory mediators. Cromolyn sodium is important for its effectiveness in preventing asthma attacks and allergic reactions. It is studied to understand its mechanism of action and to develop new and improved anti-allergic and anti-asthma drugs.'

Cromolyn Sodium: A chromone complex that acts by inhibiting the release of chemical mediators from sensitized MAST CELLS. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

disodium cromoglycate : An organic sodium salt that is the disodium salt of cromoglycic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13206344
MeSH IDM0006576
PubMed CID27503
CHEMBL ID74
CHEBI ID128458
SCHEMBL ID7500
MeSH IDM0006576

Synonyms (145)

Synonym
erythromycin lactobionate
3847-29-8
FT-0660522
6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;2,3,5,6-tetrahydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]o
fpl.670
disodium cromoglycate
sodium cromoglycate
nsc-109500
cromolyn sodium salt
sodium cromolyn
AC-18734
dscg
natrii cromoglicas
disodium 5,5'-((2-hydroxytrimethylene)bis(oxy))bis(4-oxo-4h-1-benzopyran-2-carboxylate)
5,5'-((2-hydroxytrimethylene)dioxy)bis(4-oxo-4h-1-benzopyran-2-carboxylic acid) disodium salt
4h-1-benzopyran-2-carboxylic acid, 5,5'-((2-hydroxy-1,3-propanediyl)bis(oxy))bis(4-oxo-, disodium salt)
cromoglycate disodium
dinatrium salz von 1,3-bis-(2-carboxychromon-5-yloxy)-2-hydroxypropan [german]
fpl-670
einecs 239-926-7
sodium cromoglicate [jan]
4h-1-benzopyran-2-carboxylic acid, 5,5'-((2-hydroxytrimethylene)dioxy)bis(4-oxo-, disodium salt
nsc 109500
chromolyn sodium
gastrofrenal
lomuda
cromoptic
nasalcrom
ccris 3194
cromolyn sodium [usan]
disodium 5,5'-((2-hydroxytrimethylene)dioxy)bis(4-oxo-4h-1-benzopyran-2-carboxylate)
opticrom
inostral (anti-asthmatic)
gastrocrom
natrium cromoglicat [german]
sodium cromoglicate
crolom
intal nebulizer
5,5'-(2-hydroxytrimethylenedioxy)bis(4-oxochromene-2-carboxylic acid)
15826-37-6
cromolyn disodium salt
PRESTWICK_996
cromolyn sodium
NCGC00017083-01
cas-15826-37-6
gastrocrom (tn)
sodium cromoglicate (jp17)
intal (tn)
cromolyn sodium (usp)
D00526
NCGC00094633-01
NCGC00094633-02
SPECTRUM1500210
HMS2091I06
HMS2089N09
disodium cromolyn
astilyn
cromoglicate sodium
CHEMBL74
HMS502K19
cromoglycate, sodium
cromoglycate, disodium
fpl670
cromolyn disodium
HMS1920A18
HMS1570D05
disodium 5,5'-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4h-chromene-2-carboxylate)
dinatrium salz von 1,3-bis-(2-carboxychromon-5-yloxy)-2-hydroxypropan
natrium cromoglicat
chebi:128458 ,
NCGC00021142-02
sodium 5-[3-(2-carboxy-4-oxo-chromen-5-yl)oxy-2-hydroxy-propoxy]-4-oxo-chromene-2-carboxylic acid;sodium cromoylycate
A809913
HMS2097D05
cromoglicinsaeure, dinatriumsalz
q2wxr1i0pk ,
4h-1-benzopyran-2-carboxylic acid, 5,5'-((2-hydroxy-1,3-propanediyl)bis(oxy))bis(4-oxo-, disodium salt
cromolyn sodium [usan:usp]
unii-q2wxr1i0pk
dtxsid7044554 ,
tox21_302003
NCGC00255950-01
dtxcid5024554
tox21_110863
C2521
5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis(4-oxo-4h-1-benzopyran-2-carboxylic acid) disodium salt
CCG-40261
NCGC00017083-03
NCGC00017083-02
FT-0602030
sodium salt of 5-[3-(2-carboxy-4-oxo-4h-5-chromenyloxy)-2-hydroxypropoxy]-4-oxo-4h-2-chromenecarboxylic acid
EPITOPE ID:122681
disodium 5-[3-(2-carboxylato-4-oxo-4h-5-chromenyloxy)-2-hydroxypropoxy]-4-oxo-4h-2-chromenecarboxylate
disodium 5-{3-[(2-carboxylato-4-oxo-4h-chromen-5-yl)oxy]-2-hydroxypropoxy}-4-oxo-4h-chromene-2-carboxylate
S1911
AKOS015895760
AKOS015913923
AKOS016339565
disodium cromolyn [inci]
natrii cromoglicas [who-ip latin]
cromolyn sodium [usp monograph]
cromolyn sodium [orange book]
sodium cromoglicate [who-ip]
cromolyn sodium [vandf]
sodium cromoglicate [mart.]
cromoglicate sodium [who-dd]
cromolyn disodium salt [mi]
cromolyn sodium [usp-rs]
sodium cromoglicate [ep monograph]
cromolyn (sodium)
SCHEMBL7500
tox21_110863_1
NCGC00022858-08
KS-5299
mfcd00057744
fpl 670 (cromolyn) disodium
sodium 5,5'-((2-hydroxypropane-1,3-diyl)bis(oxy))bis(4-oxo-4h-chromene-2-carboxylate)
J-009487
HMS3714D05
cromolyn sodium hydrate
cromoglycate,cromoglycic acid
sodium 5,5'-(2-hydroxypropane-1,3-diyl)bis(oxy)bis(4-oxo-4h-chromene-2-carboxylate)
disodium;5-[3-(2-carboxylato-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylate
methyl3-butynoate
disodium cromoglycate;fpl-670
cromoglicic acid;duracroman
BCP12933
Q10261779
cromolyn na
cromolina sodica
cromoglicato de sodio
cromolyne sodique
cromlyn sodio
disodium 5-(3-((2-carboxylato-4-oxo-4h-chromen-5-yl)oxy)-2-hydroxypropoxy)-4-oxo-4h-chromene-2-carboxylate
5,5'-((2-hydroxy-1,3-propanediyl)bis(oxy))bis(4-oxo-4h-1-benzopyran-2-carboxylic acid), disodium salt
cromolyn sodium (usp-rs)
disodium 5-(3-(2-carboxylato-4-oxo-4h-5-chromenyloxy)-2-hydroxypropoxy)-4-oxo-4h-2-chromenecarboxylate
sodium cromoglicate (mart.)
cromolyn sodium (usp monograph)
cromolyn sodium inhalation
cromolyn sodium oral solution (concentrate)
cromolyn sodium inhalation solution
disodium 5,5'-((2-hydroxypropane-1,3-diyl)bis(oxy))bis(4-oxo-4h-chromene-2-carboxylate)
sodium cromoglicate (ep monograph)
cromolyn sodium (usan:usp)

Research Excerpts

Overview

Cromolyn sodium is an anti-allergic drug effective for treatment in asthma and allergic rhinitis. It is a mast cell stabiliser that inhibits neutrophil activation and chemotaxis. Cromolyn sodium may have a role in the prevention of CLD.

ExcerptReferenceRelevance
"Cromolyn sodium is an anti-allergic drug effective for treatment in asthma and allergic rhinitis. "( Unraveling the thermodynamics, binding mechanism and conformational changes of HSA with chromolyn sodium: Multispecroscopy, isothermal titration calorimetry and molecular docking studies.
Qais, FA; Yasmeen, S, 2017
)
1.9
"Cromolyn sodium is an asthma therapeutic agent previously shown to reduce Aβ levels in transgenic AD mouse brains after one-week of treatment."( Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis.
Elmaleh, DR; Forte, AM; Griciuc, A; Hudry, E; Quinti, L; Ran, C; Shen, X; Tanzi, RE; Wan, Y; Ward, J; Zhang, C, 2018
)
1.2
"Cromolyn sodium is a mast cell stabiliser that inhibits neutrophil activation and neutrophil chemotaxis and therefore may have a role in the prevention of CLD."( Cromolyn sodium for the prevention of chronic lung disease in preterm infants.
Ng, G; Ohlsson, A, 2017
)
2.62
"Cromolyn sodium is a mast cell stabiliser that inhibits neutrophil activation and neutrophil chemotaxis and may, therefore, have a role in the prevention of CLD."( Cromolyn sodium for the prevention of chronic lung disease in preterm infants.
Ng, G; Ohlsson, A, 2012
)
2.54
"Cromolyn sodium is a safe compound with potent anti-allergic properties when used locally or topically. "( Development and validation of a sensitive liquid chromatographic-tandem mass spectrometric method for the determination of cromolyn sodium in human plasma.
Abbas, R; Lin, ZJ; Rusch, LM; Shum, L, 2003
)
1.97
"Cromolyn sodium is a nonsteroidal inhaled antiinflammatory agent for the treatment of asthma. "( Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial.
Blumenthal, MN; Casale, TB; Casty, FE; Fink, JN; Uryniak, T, 1998
)
1.99
"Cromolyn sodium is a mast cell stabiliser that inhibits neutrophil activation and neutrophil chemotaxis."( Cromolyn sodium for the prevention of chronic lung disease in preterm infants.
Ng, GY; Ohlsson, A, 2001
)
2.47
"Cromolyn sodium is a mast cell stabiliser that inhibits neutrophil activation and neutrophil chemotaxis."( Cromolyn sodium for the prevention of chronic lung disease in preterm infants.
Ng, GY; Ohlsson, A, 2001
)
2.47
"Cromolyn sodium is an important adjunct in the treatment of asthma."( Therapy with cromolyn sodium.
Bernstein, IL; Johnson, CL, 1978
)
1.35
"Cromolyn sodium is a recently introduced drug used in the prophylactic treatment of severe, perennial, bronchial asthma, particularly in the pediatric age group. "( Cromolyn sodium in the treatment of children with severe, perennial asthma.
Berman, BA; Fenton, MM; Girsch, LS; Haddad, ZH; Sellars, WA; Strem, EL; Thompson, HC; Wall, LE, 1975
)
3.14
"Cromolyn sodium is a highly effective topical anti-allergenic solution for the treatment of vernal, giant papillary, ragweed, and atopic conjunctivitis. "( Cromolyn sodium in ocular allergic diseases.
Goen, TM; Sieboldt, K; Terry, JE, 1986
)
3.16
"Cromolyn sodium is a valuable agent in the pharmacologic management of asthma. "( Cromolyn sodium.
Bernstein, IL, 1985
)
3.15

Effects

Cromolyn sodium (Intal) has been available in the United States to treat asthma for more than 30 years. Cromolyn sodium has a bronchial anti-inflammatory effect associated with decreased eosinophilic infiltration.

ExcerptReferenceRelevance
"Cromolyn sodium has a bronchial anti-inflammatory effect associated with decreased eosinophilic infiltration. "( Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma.
Akahori, K; Amayasu, H; Hasegawa, H; Ishizaki, Y; Nakabayashi, M; Nakagawa, H; Shoji, T; Yoshida, S, 2001
)
3.2
"Cromolyn Sodium (CS) has been used in the past as an anti-allergy drug owing to its mast cell (MC) stabilizing properties that impair histamine release. "( Cromolyn Sodium differentially regulates human mast cell and mouse leukocyte responses to control allergic inflammation.
Brüggemann, TR; Levi-Schaffer, F; Levy, BD; Mankuta, D; Pahima, H; Puzzovio, PG, 2022
)
3.61
"Cromolyn sodium has promising antipruritic efficacy and provides biochemical and histopathological recovery of the relevant parameters of cholestasis induced by bile duct ligation. "( The Investigation of Therapeutic Implications of Mast Cell Stabilizer Cromolyn Sodium on Cholestasis and Cholestatic Pruritus in Experimental Cholestasis.
Barut, F; Can, M; Hussen, SU; Özbakış Dengiz, G; Üstündağ, Y; Yılmaz Ürün, Y; Yurdakul Ertan, H, 2023
)
2.59
"Cromolyn sodium (Intal) has been available in the United States to treat asthma for more than 30 years. "( Cromolyn sodium: fitting an old friend into current asthma treatment.
Kaliner, MA; Storms, W, 2005
)
3.21
"Cromolyn sodium has been effective for the treatment of ACE inhibitor-induced cough in many case reports and has had mild success in one small clinical trial."( Cromolyn sodium for ACE inhibitor-induced cough.
Allen, TL; Gora-Harper, ML, 1997
)
2.46
"Cromolyn sodium has a bronchial anti-inflammatory effect associated with decreased eosinophilic infiltration. "( Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma.
Akahori, K; Amayasu, H; Hasegawa, H; Ishizaki, Y; Nakabayashi, M; Nakagawa, H; Shoji, T; Yoshida, S, 2001
)
3.2
"Cromolyn sodium has been reported to inhibit hypoxic pulmonary vasoconstriction (HPV) in dogs and sheep, presumably by stabilizing mast cell membranes and thereby preventing the release of mediators such as leukotrienes. "( Cromolyn sodium does not inhibit hypoxic pulmonary vasoconstriction in sheep.
Pearl, RG, 1990
)
3.16
"Cromolyn sodium has matured as a first-line drug in the management of asthma in the United States. "( Cromolyn sodium in the treatment of asthma: coming of age in the United States.
Bernstein, IL, 1985
)
3.15

Actions

Cromolyn sodium appears to inhibit capsular contracture more efficiently than montelukast and zafirlukast. Cromolyn sodium did not inhibit vancomycin-induced histamine release in RBL-1 or mast cells.

ExcerptReferenceRelevance
"Cromolyn sodium appears to inhibit capsular contracture more efficiently than montelukast and zafirlukast. "( Comparison of Cromolyn Sodium, Montelukast, and Zafirlukast Prophylaxis for Capsular Contracture.
Boynuyoğun, E; İspirli, M; Kősemehmetoğlu, K; Menkü Özdemir, FD; Üstün, GG; Uzun, H, 2022
)
2.52
"Cromolyn sodium did not inhibit vancomycin-induced histamine release in RBL-1 or mast cells."( Vancomycin-induced release of histamine from rat peritoneal mast cells and a rat basophil cell line (RBL-1).
Hoover, DM; Laska, DA; McGrath, JP; Shetler, TJ; White, SL; Williams, PD, 1991
)
1
"Cromolyn sodium did blunt the hypoxia-induced release of histamine into the circulation."( Cromolyn sodium does not prevent hypoxia-induced pulmonary hypertension in newborn and young lambs.
Frantz, EG; Schreiber, MD; Soifer, SJ, 1988
)
2.44

Treatment

Cromolyn sodium pretreatment, while attenuating the airway response, was still associated with significant falls in SGaw (22.7%) and FEV1 (7.3%) and increases in plasma histamine (0.18 to 0.27 ng/ml) FPL-57231 both prevented HPV (pretreatment) and reversed it when infused after induction of HPV.

ExcerptReferenceRelevance
"Cromolyn sodium pretreatment, while attenuating the airway response, was still associated with significant falls in SGaw (22.7%) and FEV1 (7.3%) and increases in plasma histamine (0.18 to 0.27 ng/ml).(ABSTRACT TRUNCATED AT 250 WORDS)"( Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma.
Church, MK; Durham, SR; Holgate, ST; Howarth, PH; Kay, AB; Lee, TH, 1985
)
1.3
"Cromolyn sodium aerosol pretreatment prevented antigen-induced increases in RL but not in Qbr."( Modification of bronchial blood flow during allergic airway responses.
Abraham, WM; Codias, E; Long, WM; Martinez, H; Sprung, CL; Wanner, A; Yerger, LD, 1988
)
1
"Treatment with cromolyn sodium compared to pl"( Pharmacological interventions for pruritus in adult palliative care patients.
Becker, C; Becker, G; Boehlke, C; Buroh, S; Coune, B; Hercz, D; Joos, L; Meerpohl, JJ; Schwarzer, G, 2023
)
1.25
"Treatment with cromolyn sodium or ketotifen markedly alleviated I/R-mediated kidney injury, whereas compound 48/80 further aggravated kidney injury."( Effect of Intervention in Mast Cell Function Before Reperfusion on Renal Ischemia-Reperfusion Injury in Rats.
Liu, D; Luo, L; Tong, F, 2016
)
0.77
"Pretreatment with cromolyn sodium prevented HPV, whereas infusion of cromolyn sodium after induction of HPV failed to reverse it; FPL-57231 both prevented HPV (pretreatment) and reversed it when infused after induction of HPV."( Does slow-reacting substance of anaphylaxis mediate hypoxic pulmonary vasoconstriction?
Ahmed, T; Oliver, W, 1983
)
0.59
"Pretreatment with cromolyn sodium prevented the decrease in TMV after bronchial provocation."( Mucociliary transport in allergic patients with antigen-induced bronchospasm.
Cohn, MA; Fernandez, RJ; Januszkiewicz, AJ; Mezey, RJ; Wanner, A, 1978
)
0.58

Toxicity

ExcerptReferenceRelevance
" Reversible hearing loss is an infrequently described adverse effect attributed to high-dose erythromycin therapy."( Erythromycin ototoxicity: a call to heighten recognition.
Lapp, NL; Parker, JE; Whitener, CJ, 1991
)
0.28
"We undertook a literature review to document whether certain therapeutic measures could be considered safe during pregnancy in the allergic patient."( Safety of therapy for allergic symptoms during pregnancy.
Greenberger, P; Patterson, R, 1978
)
0.26
" Studies of patients treated for more than three years continuously have failed to show evidence of toxic effects."( [The value and safety of disodium chromoglycate in asthma].
Smith, JM,
)
0.13
" Both drugs were safe for topical ophthalmic use when used four times daily for up to 28 days."( Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis.
Caldwell, DR; Drake, MM; Hartwich-Young, R; Meyer, SM; Verin, P, 1992
)
0.55
" Dietetic and pharmacological approaches are the basis of the treatment of atopic dermatitis and gamma-linolenic acid appears to be a safe and efficient additional therapy for infants and young children."( The efficacy and safety of gamma-linolenic acid in the treatment of infantile atopic dermatitis.
Agostoni, C; Banderali, G; Fiocchi, A; Riva, E; Sala, M; Signoroni, P,
)
0.13
" The tolerance of the trial medication was registered by means of global assessment, rhinoscopy, recording of adverse events and with the aid of vital and laboratory parameters."( A randomized equivalence trial comparing the efficacy and safety of Luffa comp.-Heel nasal spray with cromolyn sodium spray in the treatment of seasonal allergic rhinitis.
Gegenheimer, LH; Klein, P; Weiser, M, 1999
)
0.52
" Adverse systemic effects did not occur."( A randomized equivalence trial comparing the efficacy and safety of Luffa comp.-Heel nasal spray with cromolyn sodium spray in the treatment of seasonal allergic rhinitis.
Gegenheimer, LH; Klein, P; Weiser, M, 1999
)
0.52
" An added built-in spacer has reduced oropharyngeal deposition that may result in fewer adverse events and make it easier to use."( One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma.
Anolik, R; Gillman, SA; Newman, K; Schenkel, E, 2002
)
0.31
" The most common drug-related adverse events were cough (2% FP vs 1% SCG) and hoarseness (1% FP vs 0% SCG)."( Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing.
Allen, DB; Bisgaard, H; Davies, P; Kalev, I; Milanowski, J; Willits, L, 2004
)
0.32
" No adverse effect related with medication was observed."( A double-masked study to compare the efficacy and safety of topical cromolyn for the treatment of allergic conjunctivitis.
Chen, WL; Hou, YC; Hu, FR; Liu, YL; Wang, IJ, 2011
)
0.37
"Cromolyn 2 % ophthalmic solution was effective and safe to treat allergic conjunctivitis."( A double-masked study to compare the efficacy and safety of topical cromolyn for the treatment of allergic conjunctivitis.
Chen, WL; Hou, YC; Hu, FR; Liu, YL; Wang, IJ, 2011
)
0.37
"Permanent hearing loss is one of cisplatin's adverse effects, affecting 30-60% of cancer patients treated with that drug."( Degranulation of Murine Resident Cochlear Mast Cells: A Possible Factor Contributing to Cisplatin-Induced Ototoxicity and Neurotoxicity.
Karayay, B; Olze, H; Szczepek, AJ, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" From the results it is concluded that perioperative antibiotic therapy with erythromycin has pharmacodynamic advantages."( [Pharmacodynamics of erythromycin lactobionate during tonsillectomy in children].
Leuthardt, R; Morger, R; Trümpi, B, 1989
)
0.28
" Maximum plasma peak concentrations, time to maximum concentrations, area under plasma concentration versus time curves, half-life of elimination, and mean residence times were determined from concentration versus time curves."( Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
Lakritz, J; Marsh, AE; Mihalyi, JE; Wilson, WD, 2000
)
0.31
"Maximum peak concentration of erythromycin A after administration of erythromycin phosphate was significantly greater than after administration of erythromycin estolate (2."( Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
Lakritz, J; Marsh, AE; Mihalyi, JE; Wilson, WD, 2000
)
0.31
" The paper describes mathematical, laboratory and clinical aspects which must be examined in designing a protocol for pharmacokinetic experiments."( Pharmacokinetics--uses and abuses.
Fell, PJ; Stevens, MT, 1975
)
0.25
" The pharmacokinetic parameters derived from the intravenous administration were used to evaluate the pharmacokinetics after inhalation administration via the Spinhaler."( The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration.
Auty, RM; Brown, K; Hodder, RW; Neale, MG, 1986
)
0.27
" The synthesis and the physicochemical and pharmacokinetic evaluation of a CDS modeling the lipoyl and other ester derivatives of chlorambucil (an antineoplastic agent) and cromolyn (a bischromone used in antiasthma prophylaxis) as compared with their respective parent drugs are described."( Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue.
Bodor, N; Eberst, K; Marvanyos, E; Saah, M; Wu, WM, 1996
)
0.29
" The forced exhaled volume manoeuvres were associated with a higher Cmax and plasma concentrations up to 60 min post-inhalation (P<0."( A simple pharmacokinetic method to evaluate the pulmonary dose in clinical practice--analyses of inhaled sodium cromoglycate.
Anderson, M; Lindström, M; Meurling, L; Svartengren, K; Svartengren, M; Svensson, JO, 2004
)
0.32
" After a single dose of sodium cromoglycate, the main pharmacokinetic parameters of nasal spray and nasal drops were as follows, T(1/2)(1."( [HPLC-MS/MS method for determination of sodium cromoglycate concentration in human plasma and its pharmacokinetics].
Guo, RC; Liu, XY; Wang, BJ; Xu, XY; Yuan, GY; Zhang, R, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"Seventeen paid volunteer subjects were used in a double-blind crossover experiment to investigate the effects of disodium cromoglycate (DSCG), alone and in combination with ethanol, on human perceptual, cognitive and motor performance."( The effect of disodium cromoglycate on human performance, alone and in combination with ethanol.
Crawford, WA; Franks, HM; Hensley, VR; Starmer, GA; Teo, RK, 1976
)
0.26
"Effects of flutropium bromide, a new bronchodilator with an anticholinergic action, alone or in combination with other antiasthma drugs were investigated in guinea pigs by using an index of inhibition of the acetylcholine (ACh)-induced bronchoconstriction."( [Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction].
Misawa, M; Mizuno, H; Ohno, H; Takahashi, Y, 1990
)
0.28
" Therefore, we studied the effect of the beta2-agonist reproterol in combination with DSCG."( Effect of reproterol either alone or combined with disodium cromoglycate on airway responsiveness to methacholine.
Jörres, RA; Kanniess, F; Magnussen, H, 2005
)
0.33
"The % fall in FEV(1) from baseline and the area under the 30-min FEV(1) time curve and time to recover to 95% baseline FEV(1) were used to express protection from 40 mg sodium cromoglycate alone, and in combination with 10 mg montelukast, in subjects with asthma."( Sodium cromoglycate alone and in combination with montelukast on the airway response to mannitol in asthmatic subjects.
Anderson, SD; Brannan, JD; Caillaud, C; Perry, CP; Seale, JP, 2010
)
0.36
"To observe the clinical efficacy of sodium cromoglicate eye drops combined with Yupingfeng granules in the treatment of allergic conjunctivitis."( Efficacy of sodium cromoglicate eye drops combined with yupingfeng granules in the treatment of allergic conjunctivitis.
Chen, Y, 2013
)
0.39
" Based on the pharmacological properties of both substances, this study aimed to develop a dry powder inhaler (DPI) of SHA alone and in combination with SCG."( Sodium hyaluronate dry powder inhalation in combination with sodium cromoglycate prepared using optimized spray drying conditions.
Alparslan, L; Karasulu, E; Özdokur, KV; Yildiz Türkyilmaz, G, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability of erythromycin from the capsule was 32 +/- 7% and for the duodenal solution 43 +/- 14%."( Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin.
Bochner, F; Hetzel, D; Somogyi, AA; Williams, DB, 1995
)
0.29
" Although it is poorly absorbed after administration by mouth, disodium cromoglycate is of clinical benefit to patients with systemic mastocytosis."( Oral disodium cromoglycate in the treatment of systemic mastocytosis.
Austen, KF; Soter, NA; Wasserman, SI, 1979
)
0.26
" The experiments suggesting a relationship between the activity and the bioavailability of the ester 19 are also described."( Troponoids. 3. Synthesis and antiallergy activity of N-troponyloxamic acid esters.
Bagli, JF; Bogri, T; Lippmann, W; Martel, R; Palameta, B; Pugsley, T; Robinson, W, 1979
)
0.26
" The two absorption rate constants differed by more than an order of magnitude."( The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man.
Kellaway, IW; Stevens, J; Taylor, G; Taylor, KM, 1989
)
0.28
" Additional studies in normal volunteers showed that SCG was poorly absorbed from the gastrointestinal tract."( Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique.
Dickson, CR; Holgate, ST; Lewis, RA; Renwick, AG; Richards, R, 1987
)
0.54
" Furthermore, when non-electrolytes such as BL-9EX or urea were added to the films together with the counter-ions, the bioavailability of the drugs increased."( Enhanced percutaneous absorption of ionizable water-soluble drugs.
Ebisawa, H; Ishikura, T; Machida, Y; Nagai, T; Sakai, Y; Shishikura, T, 1987
)
0.27
" The implications of this observation pertain to both toxicity effects, when EDTA is incorporated into ocular drug products for stability purposes, and novel strategems for improving ocular bioavailability of topically applied drugs."( Effects of calcium chelating agents on corneal permeability.
Grass, GM; Robinson, JR; Wood, RW, 1985
)
0.27
"Cromolyn is a white crystalline powder which is poorly absorbed from the gastrointestinal tract."( Cromolyn sodium: a review.
König, P; Shapiro, GG,
)
1.57
" Sodium cromoglycate and nedocromil sodium, which are poorly absorbed from the gastrointestinal tract, were tested by intraperitoneal administration."( LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity.
Bonhomme, Y; Brown, T; Murray, N; Zoerkler, N, 1994
)
0.29
"The enteral bioavailability of magnesium firmly bound to a fire-proof, inert SiO2-Al2O3 matrix (ground magnesia boats) was studied in magnesium-deficient albino Sprague-Dawley rats, with and without blocking gastric hydrochloric acid secretion with omeprazole."( Erythema formation in magnesium-deficient albino rats. A non-invasive model for the screening of anti-inflammatory agents and oral mineral supplements.
Abele, C; Classen, CU; Classen, HG; Friedberg, KD; Haubold, W; Schimatschek, HF, 1993
)
0.29
"Herein we report the discovery of a group of derivatized alpha-amino acids that increase the oral bioavailability of sodium cromolyn."( Oral delivery of sodium cromolyn: preliminary studies in vivo and in vitro.
Baughman, RA; Leipold, H; Leone-Bay, A; Rivera, T; Sarubbi, D; Variano, B, 1996
)
0.29
"The absolute oral bioavailability of sodium cromolyn in the rat model is estimated to be approximately 5%."( Oral delivery of sodium cromolyn: preliminary studies in vivo and in vitro.
Baughman, RA; Leipold, H; Leone-Bay, A; Rivera, T; Sarubbi, D; Variano, B, 1996
)
0.29
"To determine if a urinary excretion method, previously described for salbutamol, could also indicate the relative bioavailability of sodium cromoglycate to the lung following inhalation from a metered dose inhaler."( Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion.
Aswania, OA; Chrystyn, H; Corlett, SA, 1999
)
0.3
" This represents the relative bioavailability of sodium cromoglycate to the lung following inhalation."( Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion.
Aswania, OA; Chrystyn, H; Corlett, SA, 1999
)
0.3
"The relative lung bioavailability of sodium cromoglycate following inhalation has been evaluated using urinary drug excretion in nine healthly volunteers."( Relative lung bioavailability of generic sodium cromoglycate inhalers used with and without a spacer device.
Aswania, O; Chrystyn, H, 2001
)
0.31
" In addition, because cromolyn is poorly absorbed systemically, it is well tolerated and not associated with drug interactions."( Use of intranasal cromolyn sodium for allergic rhinitis.
Ehrlich, PM; Fineman, SM; Meltzer, EO; Ratner, PH; Skoner, DP, 2002
)
0.65
"The relative lung and systemic bioavailability of sodium cromoglycate following inhalation by different methods have been determined using a urinary excretion pharmacokinetic method."( Relative lung and systemic bioavailability of sodium cromoglycate inhaled products using urinary drug excretion post inhalation.
Aswania, O; Chrystyn, H, 2002
)
0.31
" In order to evaluate a new approach to enhance the absorption and bioavailability of cromolyn sodium, a sensitive assay was needed to support an oral-dose study in humans."( Development and validation of a sensitive liquid chromatographic-tandem mass spectrometric method for the determination of cromolyn sodium in human plasma.
Abbas, R; Lin, ZJ; Rusch, LM; Shum, L, 2003
)
0.75
" The marker substance used to estimate the relative lung bioavailability was sodium cromoglycate (SCG), which is poorly absorbed from the gastrointestinal tract, but is completely absorbed from the lungs."( Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer.
Hühnerbein, J; Köhler, E; Schuster-Wonka, R; Sollich, V, 2003
)
0.32
" This study evaluates the relative and systemic bioavailability following inhalation of nebulized sodium cromoglycate (SCG) in healthy subjects."( A simple pharmacokinetic method to evaluate the pulmonary dose in clinical practice--analyses of inhaled sodium cromoglycate.
Anderson, M; Lindström, M; Meurling, L; Svartengren, K; Svartengren, M; Svensson, JO, 2004
)
0.32
" Mesothelial damage, angiogenesis, and fibrosis of mesentery and parietal peritoneum as well as glucose absorption rate and ultrafiltration capacity proved to be mast cell independent."( Novel role for mast cells in omental tissue remodeling and cell recruitment in experimental peritoneal dialysis.
Beelen, RH; Fabbrini, P; Hekking, LH; Keuning, ED; Ter Wee, PM; van den Born, J; Zareie, M, 2006
)
0.33
" A urinary excretion pharmacokinetic method was used to evaluate the bioavailability of the selected ternary formulae, inhaled via a Handihaler, relative to the marketed Intal Spincaps, inhaled via a Spinhaler."( Promising ternary dry powder inhaler formulations of cromolyn sodium: formulation and in vitro-in vivo evaluation.
El-laithy, HM; Elbary, AA; Tadros, MI, 2007
)
0.59
"The efficacy of n-lauryl-beta-D-maltopyranoside, (dodecylmaltoside, DDM) as a permeability-enhancer for tiludronate and cromolyn (BCS Class III, water-soluble compounds with oral bioavailability < 5%) was evaluated in Caco-2 cell monolayers and rat intestinal sacs."( Effect of dodecylmaltoside (DDM) on uptake of BCS III compounds, tiludronate and cromolyn, in Caco-2 cells and rat intestine model.
Betageri, GV; Deshmukh, DD; Nagilla, R; Ravis, WR, 2010
)
0.36
" Here, solid lipid nanoparticles (SLNs) have been developed for the purpose of oral bioavailability enhancement."( Highly water-soluble mast cell stabiliser-encapsulated solid lipid nanoparticles with enhanced oral bioavailability.
Chaubey, P; Chaurasia, S; Khan, G; Kumar, N; Mishra, B; Patel, RR, 2016
)
0.43
"Curcumin, a phytochemical present in the rhizome of Curcuma longa is well known for its anti-inflammatory activity; however, the main drawback is its poor bioavailability which limits its therapeutic approval."( Ovalbumin-induced allergic inflammation lead to structural alterations in mouse model and protective effects of intranasal curcumin: A comparative study.
Chauhan, PS; Singh, R,
)
0.13
" Cromolyn is a mast cell stabilizer and was proposed as an anticancer agent; however its high polarity limits its bioavailability by rapid washing from the body."( Cromolyn chitosan nanoparticles as a novel protective approach for colorectal cancer.
El-Maraghy, SA; ElMeshad, AN; Hammam, OA; Motawi, TK; Nady, OM, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" These findings are important in their support of the involvement of mast cells in the pathogenesis of ALS but are limited by the small effect of cromolyn, which was given intraperitoneally and is poorly absorbed after oral administration."( Amyotrophic Lateral Sclerosis, Neuroinflammation, and Cromolyn.
Theoharides, TC; Tsilioni, I, 2020
)
0.56
"82-fold increase in relative oral bioavailability when dosed to Sprague-Dawley rats in a fasted state."( Chitosan nanoparticles facilitate improved intestinal permeation and oral pharmacokinetics of the mast cell stabiliser cromoglycate.
Joyce, P; Peressin, K; Prestidge, CA; Wignall, A; Williams, DB; Wright, L, 2022
)
0.72

Dosage Studied

Cromolyn sodium significantly decreased the severity of antigen-induced bronchoconstriction. It did not affect T-cell subset composition changes at the dosage used. On the day salbutamol was given, surface area under the dose-response curve to PGF2 alpha was significantly higher.

ExcerptRelevanceReference
"9 micrograms/ml for the 40- and 25-mg/kg/day dosage groups, respectively."( Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection.
Cassell, GH; Crouse, DT; Duffy, LB; Geerts, MH; Hamrick, WB; Shoup, RE; Sims, PJ; Waites, KB, 1994
)
0.29
" The hearing loss was reversible in all cases, and subsided a few days (median = 3) after dosage reduction or drug discontinuation."( Erythromycin-induced hypoacusis: 11 new cases and literature review.
de Cos, MA; Sacristán, JA; Soto, JA,
)
0.13
"Erythromycin administered for appropriate indications and dosage adjustments in patients with impaired renal and/or liver function may prevent or reduce the incidence of erythromycin-induced hypoacusis."( Erythromycin-induced hypoacusis: 11 new cases and literature review.
de Cos, MA; Sacristán, JA; Soto, JA,
)
0.13
"In 10 anesthetized prairie dogs we determined the motility responses of the duodenum, sphincter of Oddi, and gallbladder to erythromycin infusion during a three-log dosing regimen and correlated activity with serum concentrations of the drug."( The effect of erythromycin on motility of the duodenum, sphincter of Oddi, and gallbladder in the prairie dog.
Ahrendt, SA; Kaufman, HS; Lillemoe, KD; Pitt, HA, 1993
)
0.29
"The objective of this study was to investigate the effects of intravenous erythromycin and chronic oral dosing of erythromycin on gastric emptying in patients with idiopathic or diabetic gastroparesis."( The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin.
Davenport, K; McCallum, RW; Richards, RD, 1993
)
0.29
"0 mg/kg dosage of ERY (76."( Effect of erythromycin lactobionate on myoelectric activity of ileum, cecum, and right ventral colon, and cecal emptying of radiolabeled markers in clinically normal ponies.
Lester, GD; Merritt, AM; Neuwirth, L; Rice, B; Steible, C; Vetro-Widenhouse, T, 1998
)
0.3
"25 microg/ml (reported minimum inhibitory concentration for Rhodococcus equi) for at least 4 hours after intragastric administration of erythromycin phosphate or erythromycin estolate, suggesting that the recommended dosage for either formulation (25 mg/kg, q 6 h) should be adequate for treatment of R equi infections in foals."( Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
Lakritz, J; Marsh, AE; Mihalyi, JE; Wilson, WD, 2000
)
0.31
"Although prokinetics are commonly used for management of POI in horses there is clearly a need for more controlled studies to define efficacious dosing and a need to develop new prokinetic drugs."( Survey of prokinetic use in horses with gastrointestinal injury.
Harmon, FA; Nieto, JE; Snyder, JR; Van Hoogmoed, LM,
)
0.13
" Increase of dosage did not lead to improved effectiveness."( [Parasympathicolytic drugs in treatment of obstructive lung diseases (author's transl)].
Gonsior, E; Meier-Sydow, J; Schultze-Werninghaus, G, 1979
)
0.26
" Around the clock administration is advisable, the dosage should be titrated for the individual patient, substitutions to another antihistamine should be to a different class of antihistamine, and the efficacy of any single antihistamine usually will diminish with prolonged use, either on the basis of true tolerance or because of psychic factors."( Antihistamines. Guidelines and implications.
Krausen, AS,
)
0.13
" Dose-response curves of the muM cromolyn inhibition of PS-potentiated release revealed a parallel shift, suggesting that cromolyn may compete with PS."( Relationship between phosphatidylserine and cromolyn in histamine release.
Goth, A; Knoohuizen, M; Read, GW, 1977
)
0.26
" The dosage of Phyllocontin tablets used was 12."( Monitoring response to bronchodilator therapy in asthma in childhood.
Macdonald, TH; McWilliam, R, 1979
)
0.26
" Although a relatively high chosen dosage of ketotifen was given, it does not seem capable of inhibiting mediator release from the bronchial mast-cells as DSCG does."( [Protection from exertion-induced bronchial asthma with disodium cromoglycate (DSCG) (cromolyn, lomudal, intal) and with ketotifen (zaditen). Doubly crossed double-blind study ].
Gmür, H; Scherrer, M, 1979
)
0.26
"In six patients with extrinsic bronchial asthma the inhalation of prostaglandin (PG) F2 alpha in a small dosage produced significant bronchoconstriction, whereas PGE2 produced bronchodilatation."( Atropine, sodium cromoglycate, and thymoxamine in PGF2 alpha-induced bronchoconstriction in extrinsic asthma.
Patel, KR, 1975
)
0.25
" Blood samples obtained prior to and at various times after PIC were used to measure complement and split products of complement and plasma histamine levels and to determine dose-response slopes of lymphocyte cyclic adenosine monophosphate (cAMP) following stimulation with agonists."( Inhalation challenge and pharmacologic studies of toluene diisocyanate (TDI)-sensitive workers.
Butcher, BT; Dharmarajan, V; Karr, RM; O'Neil, CE; Salvaggio, JE; Weill, H; Wilson, MR, 1979
)
0.26
" Chronic therapy may also require corticosteroids, in which case toxic effects of long-term therapy can be minimized by use of alternate-day dosage of prednisone or daily inhalation of beclomethasone dipropionate."( Management of asthma. 2. Antiasthmatic drugs.
Hendeles, L; Weinberger, M, 1977
)
0.26
" The effective dosage for each patient had to be sought individually."( Oral cromolyn therapy in patients with food allergy: a preliminary report.
Baboo, MT; Lewin, PK; Nizami, RM, 1977
)
0.26
" Variable elimination rates for the drug among individuals require careful individualization of dosage guided by measurement of serum theophylline concentration to maintain safe and effective serum theophylline concentrations."( Theophylline for treatment of asthma.
Weinberger, M, 1978
)
0.26
" The drug was insufflated by means of rectoscopic tube at the dosage of 200 mg capsules daily for 15 days."( Intal (sodium cromoglycate) therapy in ulcerative colitis.
Chachaj, W; Kuczymska-Sekieta, K; Malolepszy, J, 1977
)
0.26
" Adequate theophylline dosage is an effective bronchodilator."( Treatment of asthma in children.
Hobday, JD, 1978
)
0.26
" Dosage and technique of administration are described and it is shown that conventional drug therapy can be reduced when this drug is properly used."( [Airways obstruction and disodium-cromoglycate--a new therapeutic principle (Clinical aspects) (author's transl)].
Anolick, GP; Primer, G; Schmidt, OP, 1975
)
0.25
" The main problem with Sodium Cromoglycate is that the recommended dosage is a four times daily application and patient non-compliance is common."( Twice daily 4% Sodium Cromoglycate vs. 2% Sodium Cromoglycate used four times daily in seasonal (grass pollen) allergic conjunctivitis.
Collum, A; Collum, LM; Fitzsimon, S; Hillery, M; Jenson, JB; Pelikan, Z; Power, WJ, 1992
)
0.28
" Both the metered dose aerosol and the dry powder dosage form were formulated using these radioactive drug particles."( Nasal distribution of radioactive drug administered using two dosage forms.
Nuutinen, J; Paronen, P; Vainio, P; Vidgren, M; Vidgren, P, 1991
)
0.28
" During treatment there was a significant reduction in the required dosage of concomitant medication, a marked improvement with regard to the severity of symptoms and a significant increase in peak flow rates."( [Effectiveness and tolerance of disodium cromoglycate capsules in pellet form].
Kapfhammer, G; Tanzer, N; Vetter, N, 1990
)
0.28
" Although cromolyn sodium significantly decreased the severity of antigen-induced bronchoconstriction, it did not affect T-cell subset composition changes at the dosage used."( Antigen-induced T-cell changes: modulation by pharmacologic agents.
Gerblich, A; Salik, H; Schuyler, M; Varghese, J, 1990
)
0.68
" Thereafter, DSCG-MDI was prescribed at the dosage of two puffs (1 mg/puff) four times daily for eight weeks."( The role of disodium cromoglycate-metered dose aerosol inhaler in the management of asthma in Thai children.
Habananonda, S; Tuchinda, M; Vichyanond, P; Visitsuntorn, N, 1990
)
0.28
" In 3 of the 12 cases, we subsequently used cromoglycate and evictions in corticosteroid-dependent patients in complete remission by gradual reduction of steroid dosage in the hope of lowering the dependence threshold."( [Idiopathic nephrotic syndrome. Effect of oral cromoglycate].
André, C; Lagrue, G; Laurent, J; Rostocker, G, 1990
)
0.28
"1 X 10(-6) M) and matched placebo were administered by identical metered dose inhalers 30 min before a dose-response to sodium metabisulphite (5-100 mg ml-1) was performed."( Inhaled sodium metabisulphite induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate.
Dixon, CM; Ind, PW, 1990
)
0.28
" The dose of SP producing a 20% change in FEV1 was calculated from the individual semi-logarithmic dose-response curve (PD20)."( Bronchospasm induced by inhalation of substance P: effect of sodium cromoglycate.
Crimi, N; Mistretta, A; Oliveri, R; Palermo, B; Palermo, F; Polosa, R; Vancheri, C, 1988
)
0.27
" On the day salbutamol was given, surface area under the dose-response curve to PGF2 alpha was significantly higher and the final drop of FEV1 significantly lower than those observed on days when placebo, ipratropium bromide and cromolyn sodium were given."( Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F2 alpha-induced bronchospasm.
Georgopoulos, D; Giulekas, D; Ilonidis, G; Sichletidis, L, 1989
)
0.72
" The dose of adenosine producing a 20% change in FEV1(PD20) was calculated from the individual semi-logarithmic dose-response curves."( Comparative study of the effects of nedocromil sodium (4 mg) and sodium cromoglycate (10 mg) on adenosine-induced bronchoconstriction in asthmatic subjects.
Crimi, N; Maccarrone, C; Mistretta, A; Oliveri, R; Palermo, B; Palermo, F; Polosa, R; Vancheri, C, 1988
)
0.27
" Sodium cromoglycate (1 mg kg-1) was instilled into the nasal cavities and for comparison animals were also similarly dosed intravenously or sub-lingually."( The nasal absorption of sodium cromoglycate in the albino rat.
Brown, K; Davis, SS; Fisher, AN; Parr, GD; Smith, DA, 1985
)
0.27
" Dosage should be individualized by clinical titration, guided by measurement of serum concentrations, and continued only if well tolerated; selection of appropriate products and dosing intervals permits maintenance of acceptably stable serum concentrations."( Theophylline use: an overview.
Hendeles, L; Weinberger, M, 1985
)
0.27
" We conclude that aerosolized cromolyn sodium (a mast cell membrane stabilizing agent) modifies hypoxic pulmonary vasoconstriction; however, unlike the intravenous form, aerosolized cromolyn sodium (at the dosage used) offers a partial protection."( Modification of hypoxic pulmonary vasoconstriction by aerosolized cromolyn sodium.
Ahmed, T; Marchette, B; Oliver, W,
)
0.66
" Thirty minute infusions of DEC at respectively 100 mg, 400 mg, 2 g, 5 g, 10 g and 15 g (one dosage per dog) did not alter the hypoxic pulmonary pressor response."( Effects of diethylcarbamazine and cromolyn sodium on hypoxic pulmonary vasoconstriction in dogs.
Leeman, M; Lejeune, P; Naeije, R,
)
0.41
" MY-1250 had no effect on the norepinephrine-induced dose-response curve in isolated rat aorta."( [Cardiovascular effects of MY-5116 and MY-1250].
Hanazuka, M; Hara, Y; Horii, D; Nishi, H, 1986
)
0.27
" The air pollution dosage during exercise is much higher than during rest because of a higher ventilatory rate and both nasal and oral breathing in the former case."( Implications of air pollution effects on athletic performance.
Covert, DS; Kim, YS; Koenig, JQ; Namekata, T; Pierson, WE, 1986
)
0.27
" Twenty minutes, 2 hours, and 4 hours after each medication, airway responsiveness to isocapnic hyperventilation of cold dry air was measured by use of a standardized dose-response method."( Airway responses to hyperventilation of cold dry air: duration of protection by cromolyn sodium.
Hargreave, FE; Juniper, EF; Latimer, KM; Morris, MM; Roberts, RS, 1986
)
0.5
" Long term prophylactic inhalation of beclomethasone dipropionate in 26 children in a dosage up to 600 mcg/day before puberty and 400 mcg/day during puberty was shown not to affect growth."( Growth and childhood asthma.
Balfour-Lynn, L, 1986
)
0.27
" Cromolyn may allow the corticosteroid dosage to be reduced in severe steroid-dependent asthmatics, but it is primarily indicated for the prophylaxis of mild to moderate disease."( Cromolyn sodium: a review of mechanisms and clinical use in asthma.
Kelly, HW; Murphy, S, 1987
)
1.72
" The new metered dose aerosol delivering 5 mg of sodium cromoglycate per actuation allows greater flexibility in adjusting the dosage and frequency of administration for individual patients."( Dose-duration effect of sodium cromoglycate aerosol in exercise-induced asthma.
Patel, KR; Wall, RT, 1986
)
0.27
" When 2 or 4 weeks of continuous cromolyn therapy was given in addition to a dosage 15 minutes prior to exercise, there was no significant difference compared with acute cromolyn administration alone."( A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm.
Katz, RM; Lanier, R; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1987
)
0.27
" Thus careful instruction of patients is required to derive optimal dosing with sodium cromoglycate."( Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler.
Auty, RM; Brown, K; Neale, MG; Snashall, PD, 1987
)
0.27
" These results demonstrate for the first time a dose-response inhibition of SO2-induced bronchoconstriction in atopic subjects within a clinically acceptable dosage range and complete obliteration of SO2 sensitivity in this group with 60 mg of cromolyn pretreatment."( Therapeutic range cromolyn dose-response inhibition and complete obliteration of SO2-induced bronchoconstriction in atopic adolescents.
Bierman, CW; Furukawa, CT; Koenig, JQ; Marshall, SG; McManus, MS; Pierson, WE; Shapiro, GG; van Belle, G, 1988
)
0.27
" A treatment with NALCRON associated, in the beginning, with a diet that excludes food allergens usually produces recovery and afterwards re-introduction of allergens, if the dosage of NALCRON is adequate."( [Food allergy. Results of a multicenter study].
André, C; Spira, C, 1988
)
0.27
" The dosage of salicylazosulfapyridine and steroids she was taking, and by which the ulcerative colitis, but not the pyoderma gangrenosum could be controlled, was not increased."( Topical disodium cromoglycate in the management of pyoderma gangrenosum.
Borghi, S; Gambini, C; Massone, L; Pestarino, A, 1988
)
0.27
" Pretreatment of exercise-induced asthma is most efficient by inhaled beta 2-agonist; orally dosed beta 2-agonist is not as efficient as inhaled beta 2-agonist in the pretreatment of exercise-induced asthma."( Exercise and the asthmatic.
Bundgaard, A,
)
0.13
" Dosage was two sprays into each nostril 4 times a day."( Sodium cromoglycate/chlorpheniramine and sodium cromoglycate nasal sprays in the treatment of seasonal rhinitis.
van Niekerk, CH, 1985
)
0.27
" Only the ketotifen and clemastine groups differed significantly from the placebo group on shifting log dose-response curves of inhaled histamine."( Long-term modification on histamine-induced bronchoconstriction by disodium cromoglycate and ketotifen versus placebo.
Colas Sanz, C; de Barrio Fernandez, M; Gozalo Reques, F; Herrero Lopez, T; Rubio Sotes, M; Senent Sanchez, C, 1985
)
0.27
" New pharmacokinetic assays reveal that it exerts classic dose-response effects both in vitro and in vivo."( Cromolyn sodium in the treatment of asthma: coming of age in the United States.
Bernstein, IL, 1985
)
1.71
" There is now less reluctance to increase dosage when their efficacy becomes inadequate."( [Routine treatment methods in respiratory allergy].
Bonstein, H, 1985
)
0.27
" Both treatments were used at a dosage of 1 drop 4 times per day."( [N-acetyl-aspartylglutamic acid eye drops in allergic-type conjuctivitis. Double-blind comparative clinical study].
Bonnet, M; Ducournau, D; Lumbroso, P; Serpin, G, 1985
)
0.27
" Changes in dosage have repeatedly demonstrated a close relationship between the dose of ingested DSCG and the control of the diarrhea."( Systemic mastocytosis: control of lifelong diarrhea by ingested disodium cromoglycate.
Dolovich, J; MacMillan, AB; Osbaldeston, GJ; Punthakee, ND, 1974
)
0.25
" After eight weeks on four capsules a day the patients in each group were allocated at random so that half continued on full dosage and half on a reducing regimen."( Long-term study of disodium cromoglycate in treatment of severe extrinsic or intrinsic bronchial asthma in adults. Brompton Hospital-Medical Research Council collaborative trial.
, 1972
)
0.25
"In the isolated guinea-pig right atria and tracheal strips, both propranolol and YM-09538 caused a parallel shift of the dose-response curve for isoproterenol to the right, indicating that these two drugs block nonselectively the beta 1 1- and beta 2-adrenoceptors."( Comparison of airway obstruction induced by propranolol and YM-09538 (a combined alpha- and beta-adrenoceptor blocking drug).
Takenaka, T; Tomioka, K; Yamada, T, 1982
)
0.26
" The dose-response curve for the neurotensin effect was triphasic: and initial gentle rise, a plateau (2."( Histamine release induced by neurotensin from rat peritoneal mast cells.
Kurose, M; Saeki, K, 1981
)
0.26
" Careful dosage titration prevents adverse effects, especially when final dosage is guided by measurement of serum concentration."( Theophylline for chronic asthma: rationale for treatment, product selection, and dosage schedule.
Hendeles, L; Weinberger, M, 1983
)
0.27
" The theophylline dosage was regulated to obtain serum levels of 10 to 15 micrograms/mL by a physician not involved directly with patient care."( A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma.
Bierman, CW; Furukawa, CT; Kraemer, MJ; Pierson, WE; Shapiro, GG; Ward, DJ, 1984
)
0.52
" DSCG attenuated the acetylcholine-induced contractile responses and shifted the dose-response curve of acetylcholine downward."( Effect of disodium cromoglycate on the action of bronchoactive agents in guinea-pig tracheal strips.
Ishihara, Y; Kitamura, S; Takaku, F, 1984
)
0.27
" The methods of administration and dosage based on pharmacologic data are considered, and the potential importance of long-acting theophylline and nebulized cromolyn preparations is noted."( The relative merits of cromolyn sodium and high-dose theophylline therapy in childhood asthma.
Godfrey, S, 1980
)
0.57
" readiness for asthma in general (the crucial dosage of histamine able to induce asthma increases)."( Pharmacology of disodium cromoglycate.
Altounyan, RE, 1980
)
0.26
" Moreover, this stabilization of the airway hyperreactivity of asthma can be attained with 12-hour dosing for most patients with one of the newer formulations."( Experience with theophylline for the management of chronic asthma.
Hendeles, L; Weinberger, M, 1980
)
0.26
" Proxicromil was administered for two consecutive 3-week periods using a dosage regimen of 18 mg twice per day for the first period followed by 18 mg four times per day for the second period."( Clinical study of a new orally active chromone in asthma-proxicromil (FPL 57787).
Dahl, R, 1980
)
0.26
" Repetitive cumulative dose-response curves demonstrated a progressive decline in the response of the pulmonary circulation to histamine."( Role of histamine in regulating pulmonary vascular tone and reactivity.
Bergofsky, EH; Mahoney, WA; Porcelli, RJ; Ventura, DF, 1981
)
0.26
"A placebo-controlled double-blind crossover trial of oral sodium cromoglycate was undertaken in thirty children with atopic eczema, employing the dosage and administration schedule recommended by the manufacturers."( A controlled trial of oral sodium cromoglycate in atopic eczema.
Atherton, DJ; Elvidge, J; Soothill, JF, 1982
)
0.26
" These was a 73% reduction in theophylline dosage over-all."( Safety, efficacy and bronchodilator-sparing effects of nebulized cromolyn sodium solution in the treatment of asthma in children.
Prenner, BM, 1982
)
0.5
"Ten patients with exercise-induced asthma participated in a single-blind dose-response study comparing the protective effect of inhaled sodium cromoglycate in increasing concentrations from 2 to 40 mg/ml."( Dose-response study of sodium cromoglycate in exercise-induced asthma.
Berkin, KE; Kerr, JW; Patel, KR, 1982
)
0.26
" Percentage of dosage of beta 2 adrenergics inhaled as against the total of beta 2 (oral and inhaled)."( [Evaluation of the impact of a care program for asthmatic children on the quality of anti-asthma drug prescriptions].
Alba, F; Gimeno, J; González, M; Madridejos, R, 1995
)
0.29
"To measure specific drug compliance and dosing frequency of two asthma medications, we used medical records data and pharmacy claims data from 276 patients who had concurrent prescriptions for inhaled anti-inflammatory agents and oral theophylline."( Comparison of patients' compliance with prescribed oral and inhaled asthma medications.
Adlis, SA; Kelloway, JS; Wyatt, RA, 1994
)
0.29
" No significant differences in compliance were found relative to prescribed dosing frequency (twice daily or less compared with three times daily or more) for either medication (P = ."( Comparison of patients' compliance with prescribed oral and inhaled asthma medications.
Adlis, SA; Kelloway, JS; Wyatt, RA, 1994
)
0.29
"A reversed-phase high-performance liquid chromatography (HPLC) method is described for the determination of sodium chromoglycate (SCG) in bulk drug and pharmaceutical dosage forms (capsules, solutions, gels)."( HPLC determination of sodium cromoglycate in pharmaceutical dosage forms.
Kocić-Pesić, V; Pećanac, D; Radulović, D; Zivanović, L, 1994
)
0.29
" Guidelines of treatment were established for each clinical level considering increasing dosage of CGS, inhaled CE (up to 2 mg/day) and regular administration of Bd."( [Standards established by consensus for the treatment of bronchial asthma and its exacerbations].
Abbate, E; Figueroa Casas, JC; Gené, R; Martelli, N; Quadrelli, S; Raimondi, A; Raimondi, G; Roncoroni, AJ, 1993
)
0.29
" Reactivity was measured as the dose-response slope by taking the percent fall in FEV1 and dividing it by the dose required to induce the fall."( Acute effect of sodium cromoglycate on airway narrowing induced by 4.5 percent saline aerosol. Outcome before and during treatment with aerosol corticosteroids in patients with asthma.
Anderson, SD; du Toit, JI; Jenkins, CR; Rodwell, LT, 1994
)
0.29
" Although there was a wide range in the total amount of DSCG deposited in the airways and lungs of asthmatic children, these data seem to provide a useful guide to standardizing the dosing in inhalation therapy."( [Assessment of the amount of drug deposited in the lungs of asthmatic children using disodium cromoglycate as the marker].
Baba, M; Iwasaki, E; Yamaura, M, 1993
)
0.29
" We conclude that DSCG in this dosage probably reduces the local intestinal response but does not prevent the extraintestinal reactions."( Effect of disodiumcromoglycate on intestinal permeability changes and clinical response during cow's milk challenge.
De Monchy, JG; Heymans, HS; Van Elburg, RM, 1993
)
0.29
" The dosage was 20 mg qid via a special inhaler."( [Efficacy of disodium cromolyn in adult chronic asthma].
Ho, LI; Lien, TC; Wang, JH, 1993
)
0.29
" As compared with baseline control (regular dose of inhaled steroids), patients treated with nedocromil plus the 50 percent reduced dosage of inhaled corticosteroid consistently demonstrated comparable or better symptom control."( Nedocromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease.
Chatterjee, SS; Dorow, PD; Lal, S; Venho, KK, 1993
)
0.55
" At similar dosage conditions (one puff per nostril, four times daily, for 3 weeks), no significant differences between the treatments were discernible in the primary efficacy parameters (scores, patients' and physicians' opinion)."( Clinical efficacy of N-acetyl-aspartyl-glutamic acid nasal spray in children suffering from pollinosis: a double-blind multicentre study.
Bertrand, B; Dab, R; Daele, J; van Cauwenberge, P; van den Broeck, R, 1995
)
0.29
" Ten patients with aspirin-induced asthma underwent three bronchial challenges with a single dose of lysine acetylsalicylate (LASA) that caused a decrease in FEV1 of 25% or more in a preliminary dose-response test 30 min after inhalation of 4 mg nedocromil sodium, 10 mg sodium cromoglycate, or placebo."( Attenuation of aspirin-induced bronchoconstriction by sodium cromoglycate and nedocromil sodium.
Bianco, S; Gambaro, G; Pieroni, MG; Refini, RM; Robuschi, M; Sestini, P; Vaghi, A, 1997
)
0.3
" It is difficult to recommend an exact dose to use because of the dosing variability in the case reports."( Cromolyn sodium for ACE inhibitor-induced cough.
Allen, TL; Gora-Harper, ML, 1997
)
1.74
" Combinations as Berodual (beta 2-sympathicomimetics and anticholinergics) can decrease the dosage of the beta 2-sympathicomimetics and therefore increase the therapeutic range."( COPD: results of long-term treatment.
Schött, D; Ulmer, T, 1997
)
0.3
" The uncontrolled presence of irregular-shaped particles can introduce dosing errors due to effects on dispersion and aerodynamic behavior."( Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols.
Fults, KA; Hickey, AJ; Miller, IF, 1997
)
0.3
" The dosage reductions are all significant but with no differences between the groups."( Comparison of three treatment regimens of inhaled sodium cromoglycate in the management of adult patients with severe, steroid-dependent asthma.
Asai, S; Edwards, A; Kohno, S; Matsuo, N; Matsuse, H; Obase, Y; Sakai, H; Shimoda, T, 1998
)
0.3
" Twenty-four young male and female healthy subjects were randomly allocated in gender-balanced fashion to 4 parallel treatment groups with single and repeated dosing of either reproterol + DSCG by HFA- or CFC-MDI (each time N = 8) or placebo by HFA- or CFC-MDI (each time N = 4) using matched placebo devices thus allowing a double-blind (with regard to placebo) approach."( Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate.
de Mey, C; Hermann, R; Ruus, P; Schneider, E, 1998
)
0.3
" The choice of drug and dosage must be individualized to the patient."( Anti-inflammatory drugs for controlling asthma.
O'Connell, EJ; Volcheck, GW, 1998
)
0.3
"The aim of this study was assessment of the role of mast cells in inflammatory processes associated with keratoconus and corneal epithelial-endothelial dystrophy and clinical assessment of Lecrolin, a specially designed dosage form (eye drops) of potassium cromoglycate (intal) used as an antiallergic drug in asthma, rhinitis, etc."( [The role of the mast cells of the conjunctiva in the intercellular interactions in keratoconus and epithelial-endothelial corneal dystrophy].
Antonova, OV; Kasparov, AA; Ziangirova, GG,
)
0.13
" The newer mast-cell stabilizing agent nedocromil sodium has a similar safety profile to sodium cromoglycate, but is more potent and has a more convenient twice-daily dosing regimen."( Treating severe eye allergy.
Verin, P, 1998
)
0.3
"0 and up to 24 h post dosing and the sodium cromoglycate urinary concentration was measured using a high performance liquid chromatographic method."( Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion.
Aswania, OA; Chrystyn, H; Corlett, SA, 1999
)
0.3
"0 and 24 h collection periods following INHC dosing were 26."( Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion.
Aswania, OA; Chrystyn, H; Corlett, SA, 1999
)
0.3
" Subgroup analyses based on age, dosage of medications and timing of exercise post-inhalation were consistent with the overall pooled analyses."( Nedocromil sodium vs. sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics.
Kelly, K; Rowe, BH; Spooner, CH, 2000
)
0.31
" The selection of drugs and dosing schedules is therefore mainly guided by clinical experience."( Management of pyoderma gangrenosum.
Mokni, M; Phillips, TJ, 2001
)
0.31
" The objective of this study was to compare the year-long safety of flunisolide HFA (daily dosage 340 microg) with that of CFC beclomethasone dipropionate (BDP) (daily dosage 336 microg) and cromolyn sodium (daily dosage 6,400 microg) in children 4-11 years old with mild-to-moderate asthma."( One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma.
Anolik, R; Gillman, SA; Newman, K; Schenkel, E, 2002
)
0.5
" In this single-center, 7-day, prospective, double-blind, single-dose, crossover, parallel-group study, subjects were randomized to be bilaterally dosed with pemirolast, cromolyn, or ketorolac at each of 3 visits."( A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents.
Amdahl, L; Graves, A; Shulman, DG; Washington, C, 2003
)
0.32
"5 mg (total daily dose) once or twice daily (n = 168) or cromolyn sodium nebulizer solution 20 mg 4 times daily (n = 167) for 8 weeks, with dosage adjustment thereafter at the investigators' discretion."( Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma.
Cruz-Rivera, M; Fitzpatrick, S; Miller, CJ; Murphy, KR; Parasuraman, B, 2003
)
0.81
" Chronotherapy studies in allergic rhinitis suggest there are benefits to nighttime dosing of antiallergy medications."( Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis.
Storms, WW, 2004
)
0.32
" They do not induce tolerance, the aerosol dosage can be easily titrated for the individual, and the protective effect is immediate."( Single-dose agents in the prevention of exercise-induced asthma: a descriptive review.
Anderson, SD, 2004
)
0.32
" Lung function measures in children were higher in studies with medium BDP-equivalent steroid dosages than low BDP-equivalent dosages, while adult studies could not be compared by steroid dosage since they all incorporated similar dosages."( Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma.
Ducharme, FM; Guevara, JP; Keren, R; Nihtianova, S; Zorc, J, 2006
)
0.33
"The purpose of this study was to examine the relationship between the specific types of medication, length of use, frequency of use, and dosing time of day on the dental caries of children diagnosed with asthma."( A cross-sectional study of medication-related factors and caries experience in asthmatic children.
Chen, JW; Donovan, K; Lee, JY; Milano, M,
)
0.13
"Thirty-two Sprague-Dawley (SD) rats were randomly divided into four groups: sham group (group S), model group (group M), high and low dosage of CS groups, (treated with CS 50 mg/kg or 25 mg/kg, group C1 and C2)."( Pretreatment of cromolyn sodium prior to reperfusion attenuates early reperfusion injury after the small intestine ischemia in rats.
Cai, J; Gan, XL; Hei, ZQ; Li, SR; Luo, GJ, 2007
)
0.69
" Phospholipid (distearylphosphatidylcholine)-cholesterol-surfactant (Tween 80/sodium cholate) systems were spray-coated on beads containing cromolyn sodium and the dosage forms were characterized for vesicle formation and encapsulation efficiency."( Improved delivery of cromolyn from oral proliposomal beads.
Betageri, GV; Deshmukh, DD; Ravis, WR, 2008
)
0.55
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Its potent anti-inflammatory effects, lack of side effects, and acceptable dosing and method of delivery, as well as its special role in exercise-induced asthma, make it a very suitable choice in the initial therapy for control of asthma."( The actual role of sodium cromoglycate in the treatment of asthma--a critical review.
Eliasson, AH; Küpper, T; Netzer, NC; Voss, HW, 2012
)
0.38
" There is a need for long-term randomised controlled trials of these technologies to determine patient-focused outcomes (such as quality of life and burden of care), safe and effective dosing levels of medications and clinical outcomes (such as hospitalisations and need for antibiotics) and an economic evaluation of their use."( Nebuliser systems for drug delivery in cystic fibrosis.
Daniels, T; Mills, N; Whitaker, P, 2013
)
0.39
" Naringenin, naringenin chalcone, and quercetin all showed strong antiallergic activity after intravenous dosing (0."( In Vivo Anti-inflammatory and Antiallergic Activity of Pure Naringenin, Naringenin Chalcone, and Quercetin in Mice.
Boix Montañés, A; Escribano-Ferrer, E; Garcia-Sala, X; Lamuela-Raventos, RM; Queralt Regué, J, 2019
)
0.51
" Oral dosing of cromoglycate remains challenging due to its high solubility but low permeability across epithelial membranes in the gastrointestinal tract: effective formulation strategies are clearly needed."( Chitosan nanoparticles facilitate improved intestinal permeation and oral pharmacokinetics of the mast cell stabiliser cromoglycate.
Joyce, P; Peressin, K; Prestidge, CA; Wignall, A; Williams, DB; Wright, L, 2022
)
0.72
" The prepared probe exhibited analytical potential as an optical nanosensor for the spectrofluorimetric determination of cromolyn sodium (CRO) in its pharmaceutical dosage forms and aqueous humour."( Utilization of N,S-doped carbon dots as a fluorescent nanosensor for determination of cromolyn based on inner filter effect: application to aqueous humour.
Abd Elhaleem, SM; Belal, F; Elsebaei, F; Shalan, S, 2022
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anti-asthmatic drugA drug used to treat asthma.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.81990.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency18.17030.000221.22318,912.5098AID743036; AID743040; AID743053
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency15.08900.000214.376460.0339AID720691
retinoid X nuclear receptor alphaHomo sapiens (human)Potency12.29980.000817.505159.3239AID1159527
pregnane X nuclear receptorHomo sapiens (human)Potency61.13060.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.19330.000229.305416,493.5996AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alkaline phosphatase, germ cell typeHomo sapiens (human)IC50 (µMol)12,840.00000.60000.90001.2000AID32834; AID32835
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G protein-coupled receptor GPR35Rattus norvegicus (Norway rat)EC50 (µMol)0.98600.06110.38070.9860AID754143
G-protein coupled receptor 35Mus musculus (house mouse)EC50 (µMol)4.84000.98002.91004.8400AID754146
G-protein coupled receptor 35Homo sapiens (human)EC50 (µMol)1.26000.00202.50079.8000AID754149
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
dephosphorylationAlkaline phosphatase, germ cell typeHomo sapiens (human)
cytoskeleton organizationG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationG-protein coupled receptor 35Homo sapiens (human)
chemokine-mediated signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityG-protein coupled receptor 35Homo sapiens (human)
negative regulation of neuronal action potentialG-protein coupled receptor 35Homo sapiens (human)
positive regulation of Rho protein signal transductionG-protein coupled receptor 35Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
alkaline phosphatase activityAlkaline phosphatase, germ cell typeHomo sapiens (human)
metal ion bindingAlkaline phosphatase, germ cell typeHomo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor activityG-protein coupled receptor 35Homo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
extracellular regionAlkaline phosphatase, germ cell typeHomo sapiens (human)
plasma membraneAlkaline phosphatase, germ cell typeHomo sapiens (human)
side of membraneAlkaline phosphatase, germ cell typeHomo sapiens (human)
plasma membraneAlkaline phosphatase, germ cell typeHomo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (262)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID80580Compound was tested for the inhibition of guinea pig active lung anaphylaxis (ALA) administered intravenously; ND= No data1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID445750Antiinflammatory activity against compound 48/80-induced histamine release in rat peritoneal mast cells at 2 uM2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Diastereoisomers of 2-benzyl-2, 3-dihydro-2-(1H-inden-2-yl)-1H-inden-1-ol: potential anti-inflammatory agents.
AID182179Compound was tested for antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) model after intraperitoneal administration at a dose 10 mg/kg1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and antiallergy activity of 10-oxo-10H-pyrido[1,2-a]thieno[3,2-d]pyrimidines and 10-oxo-10H-pyrido[1,2-a]thieno[3,4-d]pyrimidines.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID754146Agonist activity at mouse GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID1537239Antiallergic activity in CD-1 mouse model of IgE/DNP-BSA-stimulated passive cutaneous anaphylaxis assessed as inhibition of vascular permeability at 4% administered topically as oil-in-water emulsion immediately after sensitization by Evans blue extravasa2019Journal of natural products, 02-22, Volume: 82, Issue:2
In Vivo Anti-inflammatory and Antiallergic Activity of Pure Naringenin, Naringenin Chalcone, and Quercetin in Mice.
AID179233Compound was tested for the inhibition of release of histamine in rat passive peritoneal anaphylaxis1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Studies on 1,2,3-triazoles. 13. (Piperazinylalkoxy) [1]benzopyrano[2,3-d]-1,2,3-triazol-9(1H)-ones with combined H1-antihistamine and mast cell stabilizing properties.
AID1123000Antiallergic activity in Wistar Charles River rat assessed as inhibition of histamine-induced passive cutaneous anaphylaxis at 10 mg/kg, iv relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID1510605Inhibition of alpha-chymotrypsin in bovine pancreas using SPpNA as substrate pretreated with enzyme for 30 mins followed by substrate addition and measured for 12 mins by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID182538Compound was tested for percent inhibition, at 1 mg/kg administered intraperitoneally against histamine1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID227618Antianaphylactic activity against IgE-mediated rat PCA model after oral administration; Not active1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
N-(4-Isoxazolylthiazol-2-yl)oxamic acid derivatives as potent orally active antianaphylactic agents.
AID1303389Inhibition of bovine testis hyaluronidase using hyaluronic acid as substrate preincubated with CaCl2 for 20 mins followed by incubation with compound for 20 mins and substrate for 10 mins by colorimetric Morgan-Elson method in presence of BSA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Interpreting the behavior of concentration-response curves of hyaluronidase inhibitors under DMSO-perturbed assay conditions.
AID183104Inhibition of histamine release by 50% in rats after intra peritoneal administration1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Nitrogen bridgehead compounds. 44. New antiallergic 4H-pyrido[1,2-a]pyrimidin-4-ones. 4.
AID176902Inhibition of antigen-induced release of histamine (AIR) by 50% in rat dosed perorally1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Synthesis of 2-(2,3-dihydro-2-oxo-1,3,4-oxadiazol-5-yl) benzo heterocycles. A novel series of orally active antiallergic agents.
AID1134402Inhibition of histamine release in Sprague-Dawley rat peritoneal mast cells at 5 uM after 10 mins by fluorimetry relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of orally active antiallergy agents.
AID182332% inhibition against anaphylactic response in rat at dose 10 mg/kg administered orally after 60 min1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
1-[Ethoxyamino)methyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepins: a new class of antianaphylactic agents.
AID181506Ability to inhibit the release of histamine in the rat peritoneal fluids by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
N-benzylpiperazino derivatives of 3-nitro-4-hydroxycoumarin with H1 antihistamine and mast cell stabilizing properties.
AID186428Tested for PCA activity of compound in rat at 1.0 mg/kg intravenous dose1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID1133605Antiallergic activity in iv dosed adrenalectomized Sprague-Dawley rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis reaction after 12 days by Evans blue staining1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and structure-activity relationships of 5H,11 H-[I]benzopyrano[4,3-g]benzopyran-9-carboxylic acids.
AID1132675Antiallergic activity in in guinea pig ileum strips assessed as inhibition of serotonin-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID749522Inhibition of human LAD2 mast cell activation assessed as compound 48/80-induced degranulation at 1000 uM incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and inhibitory activity of potent, photoswitchable mast cell activation inhibitors.
AID1134404Inhibition of egg albumin-induced allergic bronchospasm in sensitized, spontaneously breathing and anesthesized Harlan-Wistar rat assessed as drop in pulmonary arterial blood pressure at 2 mg/kg, iv administered 1 min prior to antigen challenge (Rvb = 36.1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of orally active antiallergy agents.
AID1134465Antiallergic activity in passively sensitized rhesus monkey lungs assessed as inhibition of antigen-induced histamine release at 1.3 x 10'-3 M by fluorometric analysis relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID179212Compound was tested for its ability to inhibit the histamine release from rats passively sensitized with IgE antibodies to ovalbumin (passive peritoneal anaphylaxis (PPA)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
3-(1H-tetrazol-5-yl)-4(3H)-quinazolinone sodium salt (MDL 427): a new antiallergic agent.
AID186434Tested for PCA activity of compound in rat at 5 mg/kg intravenous dose1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID89980Inhibition of anti-IgE antibody-stimulated histamine release in human basophills at 33 uM1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Novel indolecarboxamidotetrazoles as potential antiallergy agents.
AID79864Inhibitory effect on Antigen-induced SRS-A (slow reacting substance of anaphylaxis) like material release from sensitized guinea pig lung fragments at a concentration of 10 E -5 M1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
N-(4-Isoxazolylthiazol-2-yl)oxamic acid derivatives as potent orally active antianaphylactic agents.
AID179618Antiallergic activity in the passive cutaneous anaphylaxis (PCA) model in the rat was determined after iv administration1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Antiallergy agents. 2. 2-Phenyl-5-(1H-tetrazol-5-yl)pyrimidin-4(3H)-ones.
AID1134853Antiallergic activity in ip dosed Sprague-Dawley rat assessed as compound inhibition of egg albumin/Bordetulla pertusis antibody-induced passive sensitization treated 5 mins before induction by passive cutaneous anaphylaxis assay1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Antiallergic activity of tetracyclic derivatives of quinoline-2-carboxylic acid. 2. Some benzothienoquinolinecarboxylic acids.
AID187480Relative potency is evaluated1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones.
AID594177Antiallergic activity in sensitized rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis at 3 mg/kg, iv after 30 mins relative to control2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis of novel mast cell-stabilising and anti-allergic 1,2,3,4-tetrahydro-1-naphthalenols and related compounds.
AID181833Compound was evaluated in rat PCA (passive cutaneous anaphylaxis) test administered at 100 mg/kg orally and the inhibition of PCA due to inhibition of IgE mediated release was determined1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
3-(1H-tetrazol-5-yl)-4(3H)-quinazolinone sodium salt (MDL 427): a new antiallergic agent.
AID749521Inhibition of human LAD2 mast cell activation assessed as compound 48/80-induced degranulation at 100 uM incubated for 30 mins prior to compound 48/80 challenge by histamine release assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and inhibitory activity of potent, photoswitchable mast cell activation inhibitors.
AID180167Antiallergic activity against reagin induced passive cutaneous anaphylaxis reaction in rats upon intravenous administration.1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Structure--activity relationships in a series of novel 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylic acid antiallergy agents.
AID182626Anti-passive cutaneous anaphylaxis activity in rat (intravenous administration)1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Studies on antianaphylactic agents. 7. Synthesis of antiallergic 5-oxo-5H-[1]benzopyrano[2,3-b]pyridines.
AID186431Tested for PCA activity of compound in rat at 2.5 mg/kg intravenous dose1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID179607Antiallergic activity after intravenous administration using rat reaginic passive cutaneous anaphylaxis (PCA) test.1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Nitrogen bridgehead compounds. 38. New antiallergic 4H-pyrido[1,2-a]pyrimidin-4-ones. 3.
AID1134478Antiallergic activity in passively sensitized rhesus monkey lungs assessed as inhibition of antigen-induced slow reacting substance of anaphylaxis release at 5.3 x 10'-5 M relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID181829Compound was evaluated for the type-I hypersensitivity in rat POA model at a concentration of 4% administered topically.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis of chiral and achiral pyranenamine derivatives. Potent agents with topical ocular antiallergic activity.
AID177582Ability to inhibit passive cutaneous anaphylaxis in rat, when compound was injected intraperitoneally.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and antiallergic activities of 1,3-oxazolo[4,5-h]quinolines.
AID1122998Antiallergic activity in Wistar Charles River rat assessed as inhibition of histamine-induced passive cutaneous anaphylaxis at 1 mg/kg, iv relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID179619Antiallergic activity in the passive cutaneous anaphylaxis (PCA) model in the rat was determined after oral administration1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Antiallergy agents. 2. 2-Phenyl-5-(1H-tetrazol-5-yl)pyrimidin-4(3H)-ones.
AID185145The compound was tested for inhibition of rat passive cutaneous anaphylaxis at 10 mg/kg dose after intraperitoneal administration1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Synthesis and antiallergy activity of 4-oxopyrano[3,2-b]indoles.
AID168577Antiallergic activity by rat passive cutaneous anaphylaxis (PCA) assay when administered perorally at dose 100 mg/kg1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Synthesis and antiallergic activity of some quinolinones and imidazoquinolinones.
AID439102Antiallergic activity in Wistar rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis reaction at 3 mg/kg, iv treated after 48 hrs of ovalbumin challenge measured after 30 mins2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Synthesis and evaluation of dimeric 1,2,3,4-tetrahydro-naphthalenylamine and indan-1-ylamine derivatives with mast cell-stabilising and anti-allergic activity.
AID1134476Antiallergic activity in passively sensitized rhesus monkey lungs assessed as inhibition of antigen-induced slow reacting substance of anaphylaxis release at 1.3 x 10'-3 M relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID193935% inhibition of antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) test after giving intraperitoneal dose of 8 mg/kg1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Pyrido[2,1-b]quinazolinecarboxylic acids as orally active antiallergy agents.
AID1134552Antiallergic activity in sc dosed Wistar rat assessed as inhibition of passive cutaneous anaphylaxis at Tmax1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Synthesis and antiallergic activity of 2-hydroxy-3-nitro-1,4-naphthoquinones.
AID179823Tested for the antiallergic activity in rat passive cutaneous anaphylaxis (PCA) test; po1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Antiallergics: 3-(1H-tetrazol-5-yl)-4H-pyrimido[2,1-b]benzothiazol-4-ones.
AID754141Agonist activity at rat GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment at 10 uM after 90 mins by beta-galactosidase reporter gene assay relative to zaprinast2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID194780Percent inhibition at a concentration of 0.02 mg/kg in methacholine induced bronchospasm in rat1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Antiallergics: 3-(1H-tetrazol-5-yl)-4H-pyrimido[2,1-b]benzothiazol-4-ones.
AID33543Inhibition of mast cell degranulation was assessed in female albino rats at a dose of 43 umol/kg iv1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID227616Antianaphylactic activity against IgE-mediated rat passive cutaneous anaphylaxis (PCA) model after intraperitoneal administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
N-(4-Isoxazolylthiazol-2-yl)oxamic acid derivatives as potent orally active antianaphylactic agents.
AID1134849Antiallergic activity in iv dosed anti-egg albumin homocytotropic antibody-sensitized Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis reaction administered at the time of antigen egg albumin challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
N,N'-(Phenylene)dioxamic acids and their esters as antiallergy agents.
AID183731Inhibitory activity against 48/80 induced release of Histamine from isolated rat peritoneal mast cells at a dose of 10e-3 mol1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and structure-activity relationship of spiro[isochromanpiperidine] analogues for inhibition of histamine release.
AID185777Percentage inhibition at 8 mg/kg administered intraperitoneally in rat passive cutaneous anaphylaxis (PCA) test, p<0.0011983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
(E)-3-(4-Oxo-4H-quinazolin-3-yl)-2-propenoic acids, a new series of antiallergy agents.
AID182646Compound was evaluated for the type-I hypersensitivity in rat POA model after intravenous administration.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis of chiral and achiral pyranenamine derivatives. Potent agents with topical ocular antiallergic activity.
AID1133431Antiallergic activity in egg albumin-sensitized Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis compound administered ip 5 mins prior to egg albumin and Evans blue dye challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Antiallergic activity of tetracyclic derivatives of quinoline-2-carboxylic acids. 1.
AID74048Aantianaphylactic activity at the bronchopulmonary level against IgG-mediated APA model of guinea pig when administered intraperitoneally.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
N-(4-Isoxazolylthiazol-2-yl)oxamic acid derivatives as potent orally active antianaphylactic agents.
AID182544Compound was tested for percent inhibition, at 1 mg/kg administered intraperitoneally against serotonin by Dunnett''s test1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID1132685Antiallergic activity in iv dosed adrenalectomized Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis reaction after 30 mins by Evans blue staining1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID185938Percentage inhibition against passive cutaneous anaphylaxis; ND is No Data1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and antiallergic activities of 1,3-oxazolo[4,5-h]quinolines.
AID1134403Inhibition of histamine release in Sprague-Dawley rat peritoneal mast cells at 20 uM after 10 mins by fluorimetry relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of orally active antiallergy agents.
AID754125Inhibition of PDE (unknown origin)2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID326590Inhibition of histamine release from Wistar rat peritoneal mast cells at 100 uM2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacological activity of aminoindanone dimers and related compounds.
AID1132684Antiallergic activity in adrenalectomized Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis reaction at 10 mg/kg, iv after 30 mins by Evans blue staining1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID178621Inhibition of the IgE-mediated passive cutaneous anaphylaxis (PCA) reaction in rat after intravenous administration; Range 1.04-1.421988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and
AID178638Inhibition of the IgE-mediated passive cutaneous anaphylaxis (PCA) reaction in rat after oral administration; NA means Inactive1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and
AID155968Concentration required to inhibit antigen-induced release of histamine (AIR) by 50% from rat peritoneal mast cells (RMC) (in vitro)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Synthesis of 2-(2,3-dihydro-2-oxo-1,3,4-oxadiazol-5-yl) benzo heterocycles. A novel series of orally active antiallergic agents.
AID179629Antiallergic activity by passive cutaneous anaphylaxis test after intravenous administration.1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Nitrogen bridgehead compounds. 44. New antiallergic 4H-pyrido[1,2-a]pyrimidin-4-ones. 4.
AID178100Antiallergic activity is evaluated for its ability to inhibit reaginic passive cutaneous anaphylaxis (PCA) in rats dosed intravenously; Value ranges from 1-21980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Antiallergy activity of 10-oxo-10-H-pyridazino[6,1-b]quinazoline-2-carboxylic acids.
AID1137000Antiallergic activity in sc dosed Wistar rat assessed as time between compound administration and ovalbumin challenge to give maximum activity by passive cutaneous anaphylaxis assay1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
2-cyano-1,3-dicarbonyl compounds with antiallergic activity.
AID79863Inhibitory effect on Antigen-induced SRS-A (slow reacting substance of anaphylaxis) like material release from sensitized guinea pig lung fragments at a concentration of 10 E -4 M1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
N-(4-Isoxazolylthiazol-2-yl)oxamic acid derivatives as potent orally active antianaphylactic agents.
AID754149Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID1123866Antiallergic activity in po dosed Sprague-Dawley rat passive cutaneous analphylaxis model assessed as inhibition of allergic response administered 30 mins prior to antigen challenge1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
Antiallergy agents. 1. 1,6-Dihydro-6-oxo-2-phenylpyrimidine-5-carboxylic acids and esters.
AID108134Concentration required to inhibit antigen-induced release of histamine (AIR) by 50% from passively sensitized rat mast cells1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
[1,4]Benzoxazine-2,3-diones as antiallergic agents.
AID181531Antiallergic activity in in vitro antigen-induced histamine release from isolated mast cells1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones.
AID182826Ability to inhibit the passive cutaneous anaphylaxis (PCA) reaction in rats by peroral administration; Inactive1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Pyrazolo[5,1-b]quinazolin-9-ones: a new series of antiallergic agents.
AID76552Inhibition of ovalbumin-stimulated histamine release in guinea pig lung, at 75 uM compound concentration; Inactive1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Novel indolecarboxamidotetrazoles as potential antiallergy agents.
AID179231Compound was tested for the inhibition of release of extravasation in rat passive peritoneal anaphylaxis1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Studies on 1,2,3-triazoles. 13. (Piperazinylalkoxy) [1]benzopyrano[2,3-d]-1,2,3-triazol-9(1H)-ones with combined H1-antihistamine and mast cell stabilizing properties.
AID176861Antiallergic activity by rat passive cutaneous anaphylaxis (PCA) assay when administered per orally; ND means no data1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
N-(4-substituted-thiazolyl)oxamic acid derivatives, a new series of potent, orally active antiallergy agents.
AID1123867Antiallergic activity in iv dosed Sprague-Dawley rat passive cutaneous analphylaxis model assessed as inhibition of allergic response administered at the time of antigen challenge1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
Antiallergy agents. 1. 1,6-Dihydro-6-oxo-2-phenylpyrimidine-5-carboxylic acids and esters.
AID183107Inhibition of rat passive cutaneous anaphylaxis (PCA) reaction after intravenous administration1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Nitrogen bridgehead compounds. 18. New antiallergic 4H-pyrido[1,2-a]pyrimidin-4-ones. 1.
AID749527Inhibition of human LAD2 mast cell activation assessed as compound 48/80-induced degranulation incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and inhibitory activity of potent, photoswitchable mast cell activation inhibitors.
AID754147Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment at 10 uM after 90 mins by beta-galactosidase reporter gene assay relative to zaprinast2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID182785Concentration of compound intraperitoneally in passive cutaneous anaphylaxis (PCA) model for 50% inhibition in Sprague-Dawley rat1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and antiallergic activity of some acidic derivatives of 4H-pyrimido[2,1-b]benzazol-4-ones.
AID1124126Antiallergic activity in po dosed ovalbumin-sensitized CFHB rat assessed as inhibition of passive cutaneous anaphylaxis after 30 mins by Evans blue staining1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Pharmacologically active sulfoximides: 5-hexyl-7-)S-methylsulfonimidoly) xanthone-2-carboxylic acid, a potent antiallergic agent.
AID213060In vivo toxicity in mouse after oral administration with 10% aqueous acacia gum1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID183303Rat PCA Test(50% inhibition of spot areas)in the female albino rats after oral administration in 10% aqueous acacia gum1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID1134439Antiallergic activity in iv dosed rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis at ID50 treated for 30 secs followed by egg albumin-challenge measured after 30 mins relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID1134455Antiallergic activity in passively sensitized albino rat lungs assessed as inhibition of antigen-induced histamine release at 2.7 x 10'-4 M by fluorometric analysis relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1510615Inhibition of Bacillus cereus 569/H9 beta-lactamase incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID32834Concentration required for 50% inhibition of human leukocyte alkaline phosphatase in the presence of 10 mM p-nitrophenyl phosphate as substrate1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Alkaline phosphatase inhibition by a series of pyrido[2,1-b]quinazolines: A possible relationship with cromolyn-like antiallergy activity.
AID1124757Antiallergic activity against ip dosed passive peritoneal anaphylaxis rat model assessed as inhibition of histamine release in peritoneal fluid administered 30s prior to ovalbumin challenge measured per rat after 5 mins1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Aryloxyalkyloxy- and aralkyloxy-4-hydroxy-3-nitrocoumarins which inhibit histamine release in the rat and also antagonize the effects of a slow reacting substance of anaphylaxis.
AID179572In vitro ability to inhibit antigen-induced release of histamine (AIR) from rat mast cells1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and antiallergic activities of 1,3-oxazolo[4,5-h]quinolines.
AID754144Agonist activity at mouse GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment at 10 uM after 90 mins by beta-galactosidase reporter gene assay relative to zaprinast2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID1134412Inhibition of egg albumin-induced allergic bronchospasm in sensitized, spontaneously breathing and anesthesized Harlan-Wistar rat assessed as drop in mean arterial blood pressure at 2 mg/kg, iv administered 1 min prior to antigen challenge (Rvb = 49.7+/- 1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of orally active antiallergy agents.
AID568301Inhibition of IgE-induced PCA reaction in albino Swiss mouse at 3 mg/kg administered intradermally2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Synthesis and pharmacological evaluation of the individual stereoisomers of 3-[methyl(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-indanone, a potent mast cell stabilising agent.
AID227620Antianaphylactic activity at the bronchopulmonary level against IgE-mediated rat PPA model when administered orally.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
N-(4-Isoxazolylthiazol-2-yl)oxamic acid derivatives as potent orally active antianaphylactic agents.
AID1134428Inhibition of egg albumin-induced allergic bronchospasm in sensitized, spontaneously breathing and anesthesized Harlan-Wistar rat assessed as inhibition of control allergic hypotension response at 2 mg/kg, iv administered 1 min prior to antigen challenge1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of orally active antiallergy agents.
AID1537235Antiallergic activity in CD-1 mouse model of IgE/DNP-BSA-stimulated passive cutaneous anaphylaxis assessed as inhibition of vascular permeability at 0.2%, iv administered immediately after sensitization by Evans blue extravasation assay2019Journal of natural products, 02-22, Volume: 82, Issue:2
In Vivo Anti-inflammatory and Antiallergic Activity of Pure Naringenin, Naringenin Chalcone, and Quercetin in Mice.
AID1132688Antiallergic activity in in guinea pig ileum strips assessed as inhibition of histamine-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID179614Antiallergic activity in rat reaginic passive cutaneous anaphylaxis (PCA) test upon intravenous administration1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Nitrogen bridgehead compounds. 33. New antiallergic 4H-pyrido[1,2-a]pyrimidin-4-ones. 2.
AID179617Antiallergic activity in rat reaginic passive cutaneous anaphylaxis (PCA) test upon peroral administration; NA means inactive1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Nitrogen bridgehead compounds. 33. New antiallergic 4H-pyrido[1,2-a]pyrimidin-4-ones. 2.
AID1132677Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID182704Compound was tested for the inhibition of rat passive cutaneous anaphylaxis (PCA) at 10 mg/kg dose iv (5 min pretreatment)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID1134420Inhibition of egg albumin-induced allergic bronchospasm in sensitized, spontaneously breathing and anesthesized Harlan-Wistar rat assessed as inhibition of control allergic bronchospasm response at 2 mg/kg, iv administered 1 min prior to antigen challenge1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of orally active antiallergy agents.
AID182541Compound was tested for percent inhibition, at 10 mg/kg administered intraperitoneally against histamine by Dunnett's test1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID178096Inhibition of rat passive cutaneous anaphylaxis following i.p. administration; Not active.1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
5-Tetrazolecarboxamides and their salts: new orally active antiallergy agents.
AID171715Tested for antigenic challenge time, time measured was immediate when compound was administered before challenge in rat;Immed = Immediate1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID178873Compound was tested for the inhibition of rat passive cutaneous anaphylaxis (PCA) administered intraperitoneally1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID183734Inhibitory activity against 48/80 induced release of Histamine from isolated rat peritoneal mast cells at a dose of 5*10e-4 mol1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and structure-activity relationship of spiro[isochromanpiperidine] analogues for inhibition of histamine release.
AID1134493Antiallergic activity in po dosed rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Antiallergy activity of substituted 11-oxo-11 H-pyrido[2,1-b]quinazoline-8-carboxylic acids.
AID193936% inhibition of antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) test after giving peroral dose of 32 mg/kg1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Pyrido[2,1-b]quinazolinecarboxylic acids as orally active antiallergy agents.
AID227619Antianaphylactic activity at the bronchopulmonary level against IgE-mediated rat PPA model when administered intravenously.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
N-(4-Isoxazolylthiazol-2-yl)oxamic acid derivatives as potent orally active antianaphylactic agents.
AID1134401Inhibition of histamine release in Sprague-Dawley rat peritoneal mast cells at 1.25 uM after 10 mins by fluorimetry relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of orally active antiallergy agents.
AID182967Inhibition of Evans blue extravasation by 50% in rats after intra peritoneal administration1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Nitrogen bridgehead compounds. 44. New antiallergic 4H-pyrido[1,2-a]pyrimidin-4-ones. 4.
AID80583Compound was tested for the inhibition of guinea pig active lung anaphylaxis (ALA) at 100 mg/kg iv1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID183287Rat PCA Test(50% inhibition of spot areas)in the female albino rats after (ip) administration in 10% aqueous acacia gum; value ranges from 41.2-87.31987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID79865Inhibitory effect on Antigen-induced SRS-A (slow reacting substance of anaphylaxis) like material release from sensitized guinea pig lung fragments at a concentration of 10 E -6 M1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
N-(4-Isoxazolylthiazol-2-yl)oxamic acid derivatives as potent orally active antianaphylactic agents.
AID79727Compound was tested for H1-antihistamine activity in guinea pig ileum; IA = Inactive1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Studies on 1,2,3-triazoles. 13. (Piperazinylalkoxy) [1]benzopyrano[2,3-d]-1,2,3-triazol-9(1H)-ones with combined H1-antihistamine and mast cell stabilizing properties.
AID1123004Antiallergic activity in Wistar Charles River rat assessed as inhibition of histamine-induced passive cutaneous anaphylaxis at 0.1 mg/kg, iv relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID1537238Antiallergic activity in CD-1 mouse model of IgE/DNP-BSA-stimulated passive cutaneous anaphylaxis assessed as inhibition of vascular permeability at 2% administered topically immediately after sensitization by Evans blue extravasation assay relative to co2019Journal of natural products, 02-22, Volume: 82, Issue:2
In Vivo Anti-inflammatory and Antiallergic Activity of Pure Naringenin, Naringenin Chalcone, and Quercetin in Mice.
AID168578Antiallergic activity determined by rat passive cutaneous anaphylaxis (PCA) assay when administered intraperitoneally at dose 60 mg/kg1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Synthesis and antiallergic activity of some quinolinones and imidazoquinolinones.
AID1704641Antiallergic activity in iv dosed rat model of IgE-mediated passive cutaneous anaphylaxis administered 30 secs prior to IgE challenge2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.
AID1133551Antiallergic activity in Sprague-Dawley rat assessed as inhibition of egg albumin/ Hemophilus pertussis antibody-induced passive cutaneous anaphylaxis (PCA) reaction1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
(2-Carboxy-1,4-dihydro-4-oxoquinolyl)oxamic acids and (2-carboxy-1,4-dihydro-4-oxobenzo[h]quinolyl)oxamic acids as antiallergy agents.
AID1123583Antiallergic activity in iv dosed rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis dosed along with ovalbumin challenge1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
11-Oxo-11H-pyrido[2,1-b]quinazoline-8-carboxylic acid, an orally active antiallergy agent.
AID90055H1-antihistamine activity on guinea pig ileum; Inactive1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
N-benzylpiperazino derivatives of 3-nitro-4-hydroxycoumarin with H1 antihistamine and mast cell stabilizing properties.
AID185243Percent inhibition of rat passive cutaneous anaphylaxis model after intravenous administration of the 16 mM1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Alkaline phosphatase inhibition by a series of pyrido[2,1-b]quinazolines: A possible relationship with cromolyn-like antiallergy activity.
AID171713Tested for antigenic challenge time, time measured was immediate when compound was administered before challenge in rat; Immed = Immediate1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID77132Antibronchospatic activity was determined by inhibition of histamine stimulated bronchospasm in guinea pigs after (i.v.) administration1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID182773Compound was tested for antiallergic activity in the rat passive cutaneous anaphylaxis at dose 1-2 mg/kg after iv administration; Inactive1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis and antiallergy activity of 4-oxo-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidines.
AID3283550% inhibition of human placental alkaline phosphatase in the presence of 10 mM p-nitrophenyl phosphate as substrate1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Alkaline phosphatase inhibition by a series of pyrido[2,1-b]quinazolines: A possible relationship with cromolyn-like antiallergy activity.
AID1123003Antiallergic activity in Wistar Charles River rat assessed as inhibition of histamine-induced passive cutaneous anaphylaxis at 100 mg/kg, po relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID749525Inhibition of human LAD2 mast cell activation assessed as 0.1 uM compound 48/80-induced degranulation incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and inhibitory activity of potent, photoswitchable mast cell activation inhibitors.
AID1123585Antiallergic activity in po dosed rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis pretreated for 10 to 15 mins followed by ovalbumin challenge1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
11-Oxo-11H-pyrido[2,1-b]quinazoline-8-carboxylic acid, an orally active antiallergy agent.
AID185146The compound was tested for inhibition of rat passive cutaneous anaphylaxis at 2.0 mg/kg dose after intraperitoneal administration1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Synthesis and antiallergy activity of 4-oxopyrano[3,2-b]indoles.
AID186613Tested for antiallergy activity in rat passive cutaneous anaphylaxis (PCA) test at 32 mg/kg administered perorally1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
(E)-3-(4-Oxo-4H-quinazolin-3-yl)-2-propenoic acids, a new series of antiallergy agents.
AID185930Percentage inhibition against antigen-induced release of histamine (AIR) from rat mast cells; ND is No Data1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and antiallergic activities of 1,3-oxazolo[4,5-h]quinolines.
AID1132679Antiallergic activity in in guinea pig lung tissue assessed as inhibition of SRS-A production1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID326589Inhibition histamine release from Wistar rat peritoneal mast cells at 20 uM2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacological activity of aminoindanone dimers and related compounds.
AID176818Tested for anti PCA- activity when compound was administered intravenously 60 min before challenge in rat1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Cloxacepride and related compounds: a new series of orally active antiallergic compounds.
AID183339Antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) test at 32 mg/kg upon peroral administration after 10-minute pretreatment time1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and antiallergy activity of 5-oxo-5H-thiazolo[2,3-b]quinazolinecarboxylic acids.
AID1134394Antiallergic activity against egg albumin-induced anaphylaxis in iv dosed sensitized rat compound administered 15 mins prior to antigen challenge as single dose by passive cutaneous anaphylaxis test1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of orally active antiallergy agents.
AID1510602Inhibition of Enterobacter cloacae beta-lactamase incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID183343Antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) test upon intraperitoneal administration of 8 mg/kg of the compound1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and antiallergy activity of 5-oxo-5H-thiazolo[2,3-b]quinazolinecarboxylic acids.
AID1303392Inhibition of bovine testis hyaluronidase preincubated with CaCl2 for 20 mins followed by incubation with compound for 20 mins and substrate for 10 mins by colorimetric Morgan-Elson method in presence of urea2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Interpreting the behavior of concentration-response curves of hyaluronidase inhibitors under DMSO-perturbed assay conditions.
AID182635Cytoprotective activity against ethanol-induced gastric lesions in male conscious rats1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
AID1122999Antiallergic activity in Wistar Charles River rat assessed as inhibition of histamine-induced passive cutaneous anaphylaxis at 3 mg/kg, iv relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID1134438Antiallergic activity in iv dosed rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis treated for 30 secs followed by egg albumin-challenge measured after 30 mins1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID1303388Inhibition of bovine testis hyaluronidase using hyaluronic acid as substrate preincubated with CaCl2 for 20 mins followed by incubation with of compound for 20 mins and substrate for 10 mins by colorimetric Morgan-Elson method in presence of 0.05% triton 2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Interpreting the behavior of concentration-response curves of hyaluronidase inhibitors under DMSO-perturbed assay conditions.
AID1123058Inhibition of passive cutaneous anaphylaxis in ip dosed Sprague-Dawley rat1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Inhibition of rat passive cutaneous anaphylaxis by 3-(tetrazol-5-yl)quinolines.
AID1133474Antianaphylactic activity in rat mast cells assessed as inhibition of DNP-ovalbumin-induced histamine release after 15 mins by superfusion assay1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Benzopyrones. 14. Synthesis and antiallergic properties of some N-tetrazolylcarboxamides and related compounds.
AID1133374Antiallergic activity in iv dosed Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Structure-activity correlations for a series of antiallergy agents. Oxanilic, quinaldic, and benzopyran-2-carboxylic acids.
AID176699Antiallergic activity by rat passive cutaneous anaphylaxis (PCA) assay when administered iv;value ranges between (0.56-2.74)1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
N-(4-substituted-thiazolyl)oxamic acid derivatives, a new series of potent, orally active antiallergy agents.
AID1133475Antianaphylactic activity in rat mast cells assessed as inhibition of DNP-ovalbumin-induced histamine release after 15 mins by superfusion assay relative to 4-oxo-N-(5-tetrazolyl)-4H-l-benzopyran-2-carboxamide1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Benzopyrones. 14. Synthesis and antiallergic properties of some N-tetrazolylcarboxamides and related compounds.
AID178113Antiallergic property in passive cutaneous anaphylaxis (PCA) test in rats upon intraperitoneal administration1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
N-(aminophenyl)oxamic acids and esters as potent, orally active antiallergy agents.
AID1132678Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID396634Inhibition of compound-48/80 induced degranulation in Wistar rat peritoneal mast cells assessed as histamine release at 20 uM by spectrophotometry2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Synthesis and evaluation of 4-amino-3,4-dihydro-2H-naphthalen-1-one derivatives as mast cell stabilising and anti-inflammatory compounds.
AID1132676Antiallergic activity in in guinea pig ileum strips assessed as inhibition of bradykinin-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID1859258Inhibition of antigen-induced release of histamine (AIR) from rat peritoneal mast cells (RMC)2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID1421363Anti-asthmatic activity in mouse model of ovalbumin-induced asthma assessed as decrease in methacholine-induced lung resistance at 10 mg/kg, ip daily by plethysmographic method2018European journal of medicinal chemistry, Oct-05, Volume: 158Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.
AID1134456Antiallergic activity in passively sensitized albino rat lungs assessed as inhibition of antigen-induced histamine release at 5.3 x 10'-5 M by fluorometric analysis relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID1136003Antiallergic activity in Sprague-Dawley CD rat assessed as inhibition of passive anaphylaxis-induced hind paw edema at 10 mg/kg, ip relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Troponoids. 3. Synthesis and antiallergy activity of N-troponyloxamic acid esters.
AID1134453Antiallergic activity in passively sensitized albino rat lungs assessed as inhibition of antigen-induced histamine release at 1.3 x 10'-3 M by fluorometric analysis relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID182542Compound was tested for percent inhibition, at 10 mg/kg administered intraperitoneally against serotonin by Dunnett's test1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID1123001Antiallergic activity in Wistar Charles River rat assessed as inhibition of histamine-induced passive cutaneous anaphylaxis at 30 mg/kg, iv relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID182543Compound was tested for percent inhibition, at 1 mg/kg administered intraperitoneally against rat passive cutaneous anaphylaxis by Dunnett''s test1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID1122997Antiallergic activity in po dosed Wistar Charles River rat assessed as inhibition of histamine-induced passive cutaneous anaphylaxis1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID1134133Antiallergic activity in Sprague-Dawley rat assessed as inhibition of ovalbumin-induced wheal formation at 6 mg/kg, ip administered 5 mins prior to ovalbumin challenge measured after 30 mins by passive cutaneous anaphylaxis assay relative to control1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Drug-induced modifications of the immune response. 1. Substituted 1-phenylisoquinolines.
AID1149800Antiallergic activity against anti-egg albumin homocytotropic antibody injected Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis reaction administered iv at the time of egg albumin antigen challenge or ip 30 mins prior to egg alb1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Quinoline derivatives as antiallergy agents. 2. Fused-ring quinaldic acids.
AID180175The compound was evaluated for antiallergic activity against reagin induced passive cutaneous anaphylaxis reaction in rats upon peroral administration, the dose at which the compound was tested and found inactive1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Structure--activity relationships in a series of novel 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylic acid antiallergy agents.
AID178094Inhibition of rat passive cutaneous anaphylaxis following i.p. administration.1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
5-Tetrazolecarboxamides and their salts: new orally active antiallergy agents.
AID1134467Antiallergic activity in passively sensitized rhesus monkey lungs assessed as inhibition of antigen-induced histamine release at 5.3 x 10'-5 M by fluorometric analysis relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID1134492Antiallergic activity in iv dosed rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Antiallergy activity of substituted 11-oxo-11 H-pyrido[2,1-b]quinazoline-8-carboxylic acids.
AID1133290Antiallergic activity in anti-Nippostrongylus brasiliensis homocytotropic antibody-injected Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis reaction at 10 mg/kg, ip administered 15 mins prior to worm extract antigen challenge me1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Antiallergic activity of some 9H-xanthen-9-one-2-carboxylic acids.
AID1136998Antiallergic activity in sc dosed Wistar rat assessed as inhibition of ovalbumin-mediated passive cutaneous anaphylaxis by measuring wheal formation at Tmax1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
2-cyano-1,3-dicarbonyl compounds with antiallergic activity.
AID178086Inhibition of passive cutaneous anaphylaxis (PCA) in Charles Rivers Sprague-Dawley rat after intravenous administration; value range from 1.5 to 2.91983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Studies on v-triazoles. 7. Antiallergic 9-oxo-1H,9H-benzopyrano[2,3-d]-v-triazoles.
AID754128Inhibition of chloride channel (unknown origin)2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID1134466Antiallergic activity in passively sensitized rhesus monkey lungs assessed as inhibition of antigen-induced histamine release at 2.7 x 10'-4 M by fluorometric analysis relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID1133604Antiallergic activity in adrenalectomized Sprague-Dawley rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis reaction at 1 mg/kg, iv after 12 days by Evans blue staining1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and structure-activity relationships of 5H,11 H-[I]benzopyrano[4,3-g]benzopyran-9-carboxylic acids.
AID1303387Inhibition of bovine testis hyaluronidase using hyaluronic acid as substrate preincubated with CaCl2 for 20 mins followed by incubation with compound for 20 mins and substrate for 10 mins by colorimetric Morgan-Elson method2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Interpreting the behavior of concentration-response curves of hyaluronidase inhibitors under DMSO-perturbed assay conditions.
AID749523Inhibition of human LAD2 mast cell activation assessed as 1.0 uM compound 48/80-induced degranulation incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and inhibitory activity of potent, photoswitchable mast cell activation inhibitors.
AID1859259Inhibition of IgE-mediated passive cutaneous anaphylaxis in rat2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID177828Effective dose against IgE-mediated cutaneous anaphylaxis in the rat after ip administration1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents.
AID1123878Antianaphylactic activity in po dosed male Sprague-Dawley rat assessed as inhibition of egg albumin/Bordetella pertussis-induced passive cutaneous anaphylaxis reaction1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
Studies on antianaphylactic agents. 6. Synthesis of some metabolites of 6-ethyl-3-(1H-tetrazol-5-yl)chromone and their analogues.
AID179252Compound was tested in vivo for the inhibition of serotonin release in rat peritoneal cell1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID754143Agonist activity at rat GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID594181Antiallergic activity in rat Peritoneal mast cell assessed as inhibition of compound 48/80-induced histamine release at 20 uM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis of novel mast cell-stabilising and anti-allergic 1,2,3,4-tetrahydro-1-naphthalenols and related compounds.
AID1136002Antiallergic activity in Sprague-Dawley CD rat assessed as inhibition of passive anaphylaxis-induced hind paw edema at 30 mg/kg, ip relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Troponoids. 3. Synthesis and antiallergy activity of N-troponyloxamic acid esters.
AID177856Effective dose against passive cutaneous anaphylaxis in rat when administered intraperitoneally.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
[1,4]Benzoxazine-2,3-diones as antiallergic agents.
AID439095Inhibition of 48/80-induced histamine release in Wistar rat peritoneal mast cells at 2 x 10'-5 M after 5 mins2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Synthesis and evaluation of dimeric 1,2,3,4-tetrahydro-naphthalenylamine and indan-1-ylamine derivatives with mast cell-stabilising and anti-allergic activity.
AID177619Compound was evaluated in rat PCA (passive cutaneous anaphylaxis) test administered intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
3-(1H-tetrazol-5-yl)-4(3H)-quinazolinone sodium salt (MDL 427): a new antiallergic agent.
AID182786Concentration of compound perorally in passive cutaneous anaphylaxis (PCA) model for 50% inhibition in Sprague-Dawley rat; IN-Ineffective1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and antiallergic activity of some acidic derivatives of 4H-pyrimido[2,1-b]benzazol-4-ones.
AID181505Ability to inhibit the release of extravasated dye in the rat peritoneal fluids by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
N-benzylpiperazino derivatives of 3-nitro-4-hydroxycoumarin with H1 antihistamine and mast cell stabilizing properties.
AID1303391Inhibition of bovine testis hyaluronidase preincubated with CaCl2 for 20 mins followed by incubation with compound for 20 mins and substrate for 10 mins by colorimetric Morgan-Elson method in presence of up to 21% DMSO2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Interpreting the behavior of concentration-response curves of hyaluronidase inhibitors under DMSO-perturbed assay conditions.
AID91836Antiasthmatic activity against the immunoglobulin E (IgE) antigen using the human basophil asthma model.1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Preparation of triazolo[1,5-c]pyrimidines as potential antiasthma agents.
AID1133476Antiallergic activity in rat assessed as inhibition of DNP-ovalbumin-induced passive cutaneous anaphylaxis at 1 mg/kg, iv after 30 mins relative to control1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Benzopyrones. 14. Synthesis and antiallergic properties of some N-tetrazolylcarboxamides and related compounds.
AID179612Antiallergic activity against rat passive cutaneous anaphylaxis (PCA) reaction induced by 25 mg/kg of ovalbumin given iv (bolus).1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
AID1303386Inhibition of bovine testis hyaluronidase using hyaluronic acid as substrate preincubated for 20 mins followed by incubation with CaCl2 for 20 mins and substrate for 10 mins by colorimetric Morgan-Elson method2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Interpreting the behavior of concentration-response curves of hyaluronidase inhibitors under DMSO-perturbed assay conditions.
AID1124124Antiallergic activity in iv dosed ovalbumin-sensitized CFHB rat assessed as inhibition of passive cutaneous anaphylaxis after 30 mins by Evans blue staining1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Pharmacologically active sulfoximides: 5-hexyl-7-)S-methylsulfonimidoly) xanthone-2-carboxylic acid, a potent antiallergic agent.
AID1134477Antiallergic activity in passively sensitized rhesus monkey lungs assessed as inhibition of antigen-induced slow reacting substance of anaphylaxis release at 2.7 x 10'-4 M relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Pyranenamines: a new series of antiallergic compounds.
AID178098Antiallergic activity by passive cutaneous anaphylaxis test in rats by intravenous administration1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1133432Antiallergic activity in egg albumin-sensitized Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis at 25 to 50 mg/kg, po administered 15 mins prior to egg albumin and Evans blue dye challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Antiallergic activity of tetracyclic derivatives of quinoline-2-carboxylic acids. 1.
AID1134494Antiallergic activity in rat peritoneal mast cells assessed as inhibition of ovalbumin-induced histamine release after 15 mins1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Antiallergy activity of substituted 11-oxo-11 H-pyrido[2,1-b]quinazoline-8-carboxylic acids.
AID356482Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge2003Journal of natural products, Sep, Volume: 66, Issue:9
Tricin from a malagasy connaraceous plant with potent antihistaminic activity.
AID178116Antiallergic property in passive cutaneous anaphylaxis (PCA) test in rats upon oral administration; NA=Not active at 100 mg/kg1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
N-(aminophenyl)oxamic acids and esters as potent, orally active antiallergy agents.
AID439057Inhibition of compound 48/80-induced histamine release in Wistar rat peritoneal mast cell at 20 uM treated 10 mins before compound 48/80 challenge2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
A series of 1, 2-coupled indane dimers with mast cell stabilisation and smooth muscle relaxation properties.
AID179634In vivo inhibition of passive cutaneous anaphylaxis in rats when administered i.v.1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis and antiallergic properties of some 4H,5H-pyrano[3,2-c][1]benzopyran-4-one, 4H,5H-[1]benzothiopyrano[4,3-b]pyran-4-one, and 1,4-dihydro-5h-[1]benzothiopyrano[4,3-b]pyridin-4-one derivatives.
AID1150753Antiallergic activity in iv dosed sensitized Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Benzodipyran derivatives with antiallergic activity.
AID89756Inhibition of anti-IgE antibody stimulated histamine release in human lung, at 75 uM compound concentration; Inactive1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Novel indolecarboxamidotetrazoles as potential antiallergy agents.
AID179632In vivo inhibition of passive cutaneous anaphylaxis in rats when administered i.p.1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis and antiallergic properties of some 4H,5H-pyrano[3,2-c][1]benzopyran-4-one, 4H,5H-[1]benzothiopyrano[4,3-b]pyran-4-one, and 1,4-dihydro-5h-[1]benzothiopyrano[4,3-b]pyridin-4-one derivatives.
AID185274The compound was tested for inhibition of rat passive cutaneous anaphylaxis at 5.0 mg/kg dose after peroral administration; O means inactive1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Synthesis and antiallergy activity of 4-oxopyrano[3,2-b]indoles.
AID212897In vivo toxic effect was determined in mouse after intraperitoneal administration with 10% aqueous acacia gum; NA means poorly absorbed1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID1123877Antianaphylactic activity in iv dosed male Sprague-Dawley rat assessed as inhibition of egg albumin/Bordetella pertussis-induced passive cutaneous anaphylaxis reaction1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
Studies on antianaphylactic agents. 6. Synthesis of some metabolites of 6-ethyl-3-(1H-tetrazol-5-yl)chromone and their analogues.
AID1145604Antiallergic activity in po dosed Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis administered 5 mins prior to egg albumin challenge measured after 30 mins by Evan blue dye leakage assay1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Studies on antianaphylactic agents. 5. Synthesis of 3-(1H-tetrazol-5-yl)chromones, a new series of antiallergic substances.
AID182818Ability to inhibit the passive cutaneous anaphylaxis (PCA) reaction in rats by intravenous administration of 1.5 mg/kg1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Pyrazolo[5,1-b]quinazolin-9-ones: a new series of antiallergic agents.
AID181834Evaluated in rat PCA (passive cutaneous anaphylaxis) test administered at 60 mg/kg ip and the inhibition of PCA due to inhibition of IgE mediated release was determined1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
3-(1H-tetrazol-5-yl)-4(3H)-quinazolinone sodium salt (MDL 427): a new antiallergic agent.
AID181354Concentration required to inhibit Antigen-induced release of Histamine from rat mast cells1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents.
AID183733Inhibitory activity against 48/80 induced release of Histamine from isolated rat peritoneal mast cells at a dose of 2*10e-4 mol1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and structure-activity relationship of spiro[isochromanpiperidine] analogues for inhibition of histamine release.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,017)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902559 (63.70)18.7374
1990's795 (19.79)18.2507
2000's378 (9.41)29.6817
2010's232 (5.78)24.3611
2020's53 (1.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 72.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index72.66 (24.57)
Research Supply Index8.54 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index141.47 (26.88)
Search Engine Supply Index2.13 (0.95)

This Compound (72.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (16.16%)5.53%
Trials898 (21.36%)5.53%
Reviews6 (6.06%)6.00%
Reviews455 (10.82%)6.00%
Case Studies30 (30.30%)4.05%
Case Studies242 (5.76%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other47 (47.47%)84.16%
Other2,609 (62.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (18)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
WP3-Influence of Cromones on EVH-test in Young (Elite) Athletes Who Tested Positive for EIB (=Exercise Induced Bronchoconstriction) [NCT04408664]Phase 38 participants (Actual)Interventional2021-04-06Terminated(stopped due to Insufficient accrual rate)
Reverse Triple Negative Immune Resistant Breast Cancer [NCT05076682]Phase 230 participants (Anticipated)Interventional2022-06-30Recruiting
Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction [NCT03167216]Early Phase 120 participants (Actual)Interventional2017-08-01Completed
[NCT01175525]Phase 30 participants InterventionalNot yet recruiting
Cromolyn Sodium for Treatment of COVID-19 Pneumonia [NCT05077917]Phase 360 participants (Anticipated)Interventional2021-11-15Recruiting
Phase II Study of the Effect of Oral Cromolyn Sodium on Uremic Pruritus and Serum Tryptase Levels of Hemodialysed Patients [NCT00745199]Phase 262 participants (Actual)Interventional2008-05-31Completed
A Phase I/II Randomized, Open-Labeled Study to Evaluate Pharmacokinetic and Pharmacodynamic Effects and Safety of ALZT-OP1 in Subjects With Alzheimer's Disease and Normal Healthy Volunteers [NCT04570644]Phase 156 participants (Actual)Interventional2020-08-28Completed
The Role of Mast Cells on Duodenal Permeability After Duodenal Acid Perfusion in Healthy Volunteers [NCT02664051]Phase 420 participants (Anticipated)Interventional2013-08-31Recruiting
A Randomized, Open-label, Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects and the Effect of Pretreatment With Cromolyn Sodium or Albuterol Sulfate [NCT02566252]Phase 116 participants (Actual)Interventional2015-07-31Completed
Cromoglicte Adjunctive Therapy for Outpatients With Schizophrenia [NCT03794076]Phase 1/Phase 2160 participants (Anticipated)Interventional2019-04-01Recruiting
An Exploratory Study Evaluating the Efficacy of Cromoglicate Cream Compared to Cream Vehicle in the Treatment of Itch in Psoriasis [NCT01722812]Phase 230 participants (Actual)Interventional2012-11-30Completed
An Open-Label Pilot Study to Evaluate the Effectiveness and Tolerability of a Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis [NCT04846348]Phase 210 participants (Anticipated)Interventional2021-07-26Recruiting
An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema [NCT01933464]Phase 1/Phase 210 participants (Actual)Interventional2013-08-31Completed
A Phase II Exploratory Study Evaluating the Efficacy of Topical Cromoglicate Solution Compared to Topical Solution Vehicle in the Treatment of Mastocytosis [NCT01701843]Phase 27 participants (Actual)Interventional2012-10-31Terminated(stopped due to prematurely terminated because of low recruitment)
Development and Validation of Test for Gastro-esophageal Reflux and Aspiration [NCT01841307]Phase 116 participants (Actual)Interventional2015-07-31Terminated(stopped due to Difficulty recruiting; Funding ended; interim analysis provided sufficient data for interpretation.)
A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis [NCT02371941]Phase 416 participants (Actual)Interventional2014-12-31Completed
A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI) [NCT03202147]Phase 20 participants (Actual)Interventional2023-12-31Withdrawn(stopped due to Study halted prematurely prior to initiation but potentially will resume in the future.)
A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS) [NCT04428775]Phase 212 participants (Actual)Interventional2020-09-08Terminated(stopped due to Low enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01933464 (4) [back to overview]Change in Facial Erythema
NCT01933464 (4) [back to overview]Change in Matrix Metalloproteinase Activity
NCT01933464 (4) [back to overview]Facial Erythema
NCT01933464 (4) [back to overview]Matrix Metalloproteinase Activity Levels
NCT02371941 (2) [back to overview]Peak Esophageal Eosinophil Count
NCT02371941 (2) [back to overview]Symptoms as Measured by Pediatric Eosinophilic Esophagitis Symptom Score

Change in Facial Erythema

We will measure participants' change in facial erythema over the course of the study. The change in facial erythema is measured as a difference between the final (8 weeks after baseline) and baseline visit of the sum of the CEA scores determined from the 5 designated locations (nose, glabella, left cheek, right cheek, and chin). The scale range from -20 to 20. A negative score indicates improvement of facial erythema from baseline to 8 weeks after baseline. A positive score indicates worsening of facial erythema from baseline to 8 weeks after baseline. (NCT01933464)
Timeframe: Baseline and 8 weeks

Interventionscore on a scale (Mean)
Cromolyn-1.6
Vehicle-0.8

[back to top]

Change in Matrix Metalloproteinase Activity

We will compare subjects' matrix metalloproteinase activity levels at the beginning of the study (baseline) to those at the end of the study (8 weeks after baseline). Tape stripping methods were used to isolate matrix metalloproteinase(MMP). Total-MMP activity was determined with total-MMP fluorogenic substrate (5 μM; Enzo Life Sciences), in protein extracts, and subsequently measuring activity (Vmax/sec) at a fluorescence excitation wavelength 328 nm and an emission wavelength of 400 nm in a fluorescence plate reader (Gemini EM microplate spectrofluorometer). (NCT01933464)
Timeframe: Baseline and 8 weeks

InterventionVmax/sec (Median)
Cromolyn-0.005
Vehicle0.005

[back to top]

Facial Erythema

Facial erythema will be measured using the Clinician's Erythema Assessment(CEA) applied to 5 areas of the subject's face (chin, nose, glabella, left cheek, right cheek), as well as using measurements from a colorimeter applied to each of the 5 locations previous mentioned. Each area is rated from 0-4, where 4 represents the most facial erythema (worst outcome). The scores for the 5 locations are summed with a CEA total score scale of 0-20. (NCT01933464)
Timeframe: Baseline

Interventionscore on a scale (Mean)
Cromolyn6.6
Vehicle6

[back to top]

Matrix Metalloproteinase Activity Levels

Tape stripping methods were used to isolate matrix metalloproteinase(MMP). Total-MMP activity was determined with total-MMP fluorogenic substrate (5 μM; Enzo Life Sciences), in protein extracts, and subsequently measuring activity (Vmax/sec) at a fluorescence excitation wavelength 328 nm and an emission wavelength of 400 nm in a fluorescence plate reader (Gemini EM microplate spectrofluorometer). (NCT01933464)
Timeframe: Baseline

InterventionVmax/sec (Median)
Cromolyn0.02
Vehicle0.02

[back to top]

Peak Esophageal Eosinophil Count

Measure of the peak esophageal eosinophil count on esophageal biopsy specimens after 2 months of therapy (NCT02371941)
Timeframe: 2 months

InterventionPeak # of eosinophils counted per field (Median)
Oral Cromolyn57.3
Placebo71.3

[back to top]

Symptoms as Measured by Pediatric Eosinophilic Esophagitis Symptom Score

"Symptom scores will be measures at baseline, 1 month, and 2 months using a symptom scoring assessment tool known as the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS).~The PEESS is a validated symptom score that is completed by the parent of the patient.~It encompasses frequency and severity of EoE related symptoms over the past month.~The minimum score = 0. The max score = 98 The higher the score/value, the more severe and/or frequent the symptoms and therefore a worse outcome." (NCT02371941)
Timeframe: Baseline as compared to 2 months

,
Interventionunits on a scale (Mean)
Baseline PEES score2 month PEES score
Oral Cromolyn37.8917.5
Placebo30.322.3

[back to top]